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ABSTRACT 
 
Human Immunodeficiency Virus-Protease Inhibitors (HIV-PIs) are 
peptidomimetic drugs used in AIDS therapy to inhibit HIV infection by 
blocking viral protease. The advent of these drugs has led to a reduced 
incidence of HIV-associated tumors, particularly Kaposi’s sarcoma, non-
Hodgkin’s lymphoma and cervical cancer. Many studies have also reported an 
anti-proliferative non-virological action of HIV-PIs in HIV-free models leading 
them to be further investigated as anti-cancer drugs. In particular HIV-PIs affect 
several pathways involved in tumor-cell proliferation and survival, 
angiogenesis, invasion, inflammation, and antitumor immunity in HIV-free 
models. 
The most effective anti-cancer HIV-PIs is nelfinavir, that is in clinical trial  
for several tumor types, thus encouraging the study of the intracellular 
pathways at the basis of their anti-tumor activity. The anti-tumoral effects of 
nelfinavir have been related to inhibition of Akt activation, but to date the 
molecular mechanism at the basis of anti-cancer activity in breast cancer is 
poorly understood. 
My results suggest an anti-proliferative activity of nelfinavir in a panel of 
cancer cell lines. In particular, nelfinavir induces apoptosis and necrosis in 
breast cancer cell lines such as MDA-MB231 and MCF-7 cells by affecting cell 
cycle in a cell line dependent way. The anti-tumor activity of nelfinavir is 
linked to the perturbation of cellular redox state; resulting in an increase of 
intracellular reactive oxygen species (ROS) production in breast cancer cells 
but not in normal breast epithelial cells. Nelfinavir treated tumor cells show 
also a downregulation of akt pathway due to the disruption of akt-Heat Shock 
Protein 90 kDa (HSP90) complex that is induced by nelfinavir and subsequent 
degradation of akt via proteasome. These effects result to be ROS dependent. 
Since treatment with anti-oxidant free radical scavenger tocopherol restores akt 
expression levels as well as  viability of nelfinavir-untrated cells, the increase 
of ROS production represents the main and  necessary molecular mechanism to 
induce cell death in breast cancer cell lines. The anti-cancer effectiveness of 
nelfinavir has motivated its use as lead compound in this study to design novel 
anti-tumoral compounds. Primary screening  has led to the identification of 
novel nelfinavir-derivative (4n) with a high anti-cancer efficacy (IC50 50nM), 
that is a promising molecule to further evaluate for cancer therapy. 
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1. INTRODUCTION 
 
 
  1.1 HIV-PIs AND IMMUNODEFICIENCY SYNDROME  
 
HIV is a lentivirus responsible for acquired immunodeficiency syndrome 
(AIDS), a condition that in humans determines progressive failure of the 
immune system and allows life-threatening opportunistic infections and cancers 
to thrive (Munoz et al. 1993; Weiss 1993; Monini et al. 2004). HIV-Protease 
Inhibitors (HIV-PIs) have been rationally designed to block  HIV aspartyl 
protease, a viral enzyme that cleaves the HIV gag and gag-pol polyprotein 
backbone at nine specific cleavage sites to produce shorter and functional 
protein (Deeks et al. 1997). Three of the nine cleavage reactions occur between 
a phenylalanine or a tyrosine and a proline. Since none of the known 
mammalian endopeptidases cleaves before a proline, HIV-PIs have been 
designed to mimic the phenylalanine-proline peptide bond thus determinig 
tolerable toxicity and mild side effects (Monini et al. 2003).  
 
 
 
Figure 1. Protease inhibitors: mechanisms of action 
Core proteins of HIV-1 are produced as part of long polypeptides that are cut into smaller 
pieces by protease to create functional and mature proteins. Protease inhibitors bind to the 
active site, where protein cleavage occurs. With the inhibition of protease, new viral particles 
cannot mature and do not become infectious.  
 
HIV-PIs, combined with reverse transcriptase-nucleoside inhibitors 
(NRTIs) are included in the highly active antiretroviral therapy (HAART) that 
significantly improved the clinical management of HIV-1 infected patients 
and currently makes the acquired immunodeficiency syndrome a chronic, 
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manageable disease. The rationale for these combination therapies is to 
inhibit several steps of the viral life cycle. Combination regimens based on 
HIV-PIs and NNRTIs are more effective than single or dual combination of 
NRTIs in suppressing HIV replication, and in preserving or reconstituting 
both naive and memory T-lymphocytes repertories. Indeed, HAART 
suppresses HIV replication and can lead to a large reduction in HIV plasma 
viremia, restoration of normal numbers of CD4-positive T lymphocytes, 
immunological recovery, and reduction of morbidity and mortality related to 
HIV and opportunistic infections (Sgadari et al. 2003; Monini et al. 2004). 
The first HIV-PIs approved by FDA, is saquinavir, a peptidomimetic 
hydroxyethylamine. It is a transition state analogue of a native substrate of the 
HIV protease and It has a decahydroisoquinoline (DIQ) important substituent 
that improves aqueous solubility and potency by limiting the conformational 
freedom of the inhibitor (Wlodawer 2002). 
Ritonavir, a peptidomimetic HIV protease inhibitor (Flexner 2007), was 
designed by removing terminal phenyl residues and laying pyridyl groups 
instead to add water solubility (Wlodawer 2002).  As it is a strong inhibitor of 
the cytochrome P450 enzyme mediated metabolism, it is used in a 
combination therapy with other protease inhibitors, increasing plasma 
concentrations of agents that are primarily metabolized by cytochrome P450 
(Wlodawer 2002). 
Indinavir, is a peptidomimetic hydroxyethylene HIV protease inhibitor 
(Flexner 2007), designed by molecular modeling and the X-ray crystal 
structure analysis of the inhibited enzyme complex. The terminal phenyl 
constituents contribute hydrophobic binding to increase potency (Wlodawer 
2002). 
Nelfinavir was the first protease inhibitor that was not peptidomimetic. 
In the design process of nelfinavir, iterative protein cocrystal structure 
analysis of peptidic inhibitors was used and parts of the inhibitors were 
replaced by nonpeptidic substituents (Wlodawer 2002). Nelfinavir contains a 
novel 2-methyl-3-hydroxybenzamide group, whereas its carboxyl terminal 
contains the same DIQ group as saquinavir.   Nelfinavir was the first protease 
inhibitor to be indicated for pediatric AIDS (Wlodawer 2002). 
 Amprenavir is an N,N-disubstituded amino-sulfonamide nonpeptide 
HIV protease inhibitor. It has a core similar to that of saquinavir but with 
different functional groups on both ends that make its structure  easier to 
synthesize and gives better oral bioavailability (Wlodawer 2002). 
Lopinavir was originally designed to diminish the interactions of the 
inhibitor with Val82 of the HIV-1 protease, a residue that is often mutated in 
the drug resistant strains of the virus (Wlodawer 2002). Fosamprenavir is a 
phosphoester prodrug that is rapidly and extensively metabolized to 
amprenavir (Luber et al. 2007). Its solubility and bioavailability are better 
than amprenavir resulting in reduced daily pill burden (Chapman et al. 2004). 
Atazanavir is an azapeptide protease inhibitor (Flexner 2007) that shows 
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better resistant profiles than previous HIV protease inhibitors (Yanchunas et 
al. 2005).  
Tipranavir is a nonpeptidic HIV-1 protease inhibitor developed from a 
nonpeptidic coumarin template and its antiprotease activity was discovered 
by high-throughput screening (Larder et al. 2000). It possesses broad antiviral 
activity against multiple protease inhibitor resistant HIV-1 (Doyon et al. 
2005). 
Darunavir reached the market in 2006 (Flexner 2007) and is a non-
peptidic analogue of amprenavir, with a critical change at the terminal 
tetrahydrofuran (THF) group. Instead of a single THF group, darunavir 
contains two THF groups fused in the compound, to form a bis-THF moiety 
which makes it more effective than amprenavir. With this structural change, 
the stereochemistry around the bis-THF moiety confers orientational changes, 
that allows for continued binding with the protease which has developed a 
resistance for amprenavir (McCoy 2007). Therefore, darunavir has been 
designed to form robust interactions with the protease enzyme from many 
strains of HIV, including strains from patients with multiple resistance 
mutations to HIV-PIs (Chow et al. 2009). All the HIV protease inhibitors on 
the market contain a central core motif consisting of a hydroxyethylen 
scaffold, with the only exception being the central core of tipranavir, which is 
based on a coumarin scaffold (De Clercq 2009). A very important group on 
the HIV protease inhibitors is a hydroxyl group on the core motif which 
forms a hydrogen bond with the carboxylic acid on the Asp-25 and Asp-25´ 
residues in the binding site (Mimoto et al. 2000; Liu et al. 2008). Hydrogen 
bonds between the water molecule, which is linked to Ile50 and Ile50', and 
carbonyl groups of the peptidomimetic inhibitors seem to connect them with 
the flap regions (Wlodawer 2002). On the other hand, on the nonpeptidic 
inhibitors, there is a proton acceptor which replaces the tetracoordinated 
water molecule and interacts directly with the two Ile50 residues on the flap 
of the enzyme (Lebon and Ledecq 2000). 
CTP-518 is a novel HIV protease inhibitor developed by replacing 
certain key hydrogen atoms of atazanavir with deuterium. Pre-clinical studies 
demonstrated that this modification fully retains the antiviral potency but can 
evidently slow hepatic metabolism and thereby increase the half life and 
plasma levels. CTP-518, therefore, has the potential to be the first HIV 
protease inhibitor to eliminate the need to co-dose with a boosting agent, such 
as ritonavir (http://www.concertpharma.com/CTP518Ph1bStudy.htm).  
On the other hand, the clinical employment of these drugs is limited by 
many side effects such as diabetes, atherosclerosis, and cardiovascular 
complications (Carr et al. 1998; Ben-Romano et al. 2004; Chai et al. 2005), 
and the more recent HIV-PIs have only slightly reduced the toxic effects in 
clinical use. 
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Figure 2. HIV-PIs structure Mechanism of action of protease inhibitors based on a 
hydroxyethylene scaffold, which mimics the normal peptide linkage cleaved by the HIV 
protease. 
 
 
 
1.2 HIV-PIs AND CANCER 
 
HIV infection is associated with an increased risk of certain AIDS-
defining tumors: Kaposi's sarcoma, non-Hodgkin's lymphoma, and invasive 
cervical cancer (Monini et al. 2004). However, other types of cancer,  such as 
Hodgkin's disease, anal cancer, lung cancer, and testicular germ cell tumors are 
more common among HIV-infected subjects compared to the general 
population. These malignancies have been referred to as AIDS-associated 
malignancies. Although it remains unclear whether HIV acts directly as an 
oncogenic agent, it may contribute to the development of malignancies through 
several mechanisms such as infection by oncogenic viruses, failure of immune 
surveillance, and imbalance between cell proliferation and differentiation 
(Barbaro and Barbarini 2007). The advent of the HAART has led to a reduced 
incidence and/or regression of AIDS-defining tumors. This effect cannot be 
explained by the ability of these drugs to suppress HIV replication and thereby 
reconstitute the immune system: indeed tumor development is not  correlated 
with a patient's viral load or level of immune reconstitution (Monini et al. 
2004). These have been the earliest clinical indications that HIV-PIs antitumor 
activity has a non immune mediated mechanism. Many studies attempted to 
evaluate anti-cancer activity of the most widely used HIV-PIs, including 
ritonavir, saquinavir, indinavir and nelfinavir in HIV-free models. HIV-PIs 
directly affect many steps of tumor cell progression that lead from carcinoma in 
situ to invasive cancer and metastasis formation. At concentrations similar or 
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above therapeutic peak levels, HIV-PIs promote apoptosis and inhibit 
proliferation of tumor cells with little or no effects on survival and proliferation 
of normal cells (Gaedicke et al. 2002; Pati et al. 2002), furthermore inhibiting 
tumor angiogenesis and cancer-cell invasion (Pomerantz and Horn 2003). The 
HIV-PIs affected steps of tumor progression are described in Figure 3.  
 
 
Figure 3. Steps in tumor progression and metastasis affected by HIV-PIs Tumor pathways 
that underlie the various steps of cancer development can be disrupted by HIV-PIs. These steps 
usually lead to progression of in situ carcinoma (a) to invasive cancer (b) and to metastasis 
formation and dissemination (c–f). These processes are all affected by HIV-PIs through their 
ability to inhibit cytokine and chemokine production, cell activation, and basal membrane and 
ECM degradation and remodelling. 
 
First, these drugs influence tumor cell proliferation, thus limiting tumor 
growth and invasion. As metastatic cell clones emerge, tumor cells loosen their 
contact with surrounding cells and the extracellular matrix (ECM), leading to 
invasion of blood or lymphatic vessels, and to extravasation of tumor cells at 
distant sites. These steps require the degradation of basement membranes and, 
at the same time, inhibition of apoptosis following loss of cell anchorage 
(anoikis), processes that are also inhibited by HIV-PIs. To invade neighboring 
tissue and metastasize, tumor cells require the presence of other cells such as 
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activated endothelial cells, stromal and immune cells. These cells are able to 
destroy basement membrane and ECM, modify the ECM composition, release 
ECM-bound growth and angiogenic factors, produce cytokines and chemokines 
that stimulate tumor-cell growth and migration. All these processes sustain 
tumor growth and invasion, regulating local immunity. In this context, HIV-PIs 
exert remarkable immunomodulatory effects through their ability to inhibit 
cytokine and chemokine production, cell activation, basal membrane and ECM 
degradation and remodeling. In particular, it has been demonstrated that 
ritonavir and saquinavir inhibit the production and/or release of TNF-alpha, IL-
6 and IL-8 by peripheral-blood mononuclear cells and endothelial cells (Pati et 
al. 2002). Furthermore, ritonavir inhibits the expression by endothelial cells of 
adhesion molecules, including Vascular Cell Adhesion Molecule  (VCAM), 
Intercellular Adhesion Molecule 1 (ICAM1), and selectin E, which mediate 
leukocyte recruitment at sites of inflammation (Pati et al. 2002). HIV-PIs also 
regulate tumor immunity directly by modulating antigen processing, T-cell 
survival and dendritic cell maturation and function. In particular, differentiation 
of human circulating monocytes in the presence of these drugs leads to the 
generation of dendritic cell that fail to terminally differentiate and sustain the 
inflammatory process (Sloand et al. 1999; Lu and Andrieu 2000; Giardino 
Torchia et al. 2010). The most prominent mechanism underlying these HIV-PIs 
antitumoral effects is likely to be matrix metalloproteinases (MMP) inhibition, 
that is not only responsible for the blockage of cell invasion but is also 
involved in several crucial immunomodulatory functions as well as in cancer 
mediated immune suppression (Barillari et al. 2012). Evidences indicate that 
MMPs participate in antigen processing and modulate inflammatory cytokines 
and chemokines (Lopez et al. 2000). In summary, HIV-PIs block angiogenesis 
and tumor cell invasion, inhibit endothelial and tumor cell growth by inducing 
tumor cell apoptosis, thus modulating cell-mediated cytotoxic responses 
(Toschi et al. 2011). Many other molecular mechanisms have been suggested to 
explain the anticancer activity of these drugs but the primary targets are still 
unknown. To date, some HIV-PIs are in phase I/phaseII clinical trials for 
several tumor types, thus encouraging the study of the intracellular pathways at 
the basis of their anti-tumoral activity and of novel, more effective derivatives.  
The identification of new activity for approved drugs is termed 
“repositioning”. It takes advantage of avaiable pharmacokinetic and toxicity 
data on existing drugs, limits risk and costs to pharmaceutical companies, and 
expedites the sustainable evaluation and movement of new cancer therapies to 
the clinic (Gills et al. 2007). 
 
Molecular mechanisms at the basis of anti-tumoral activity of nelfinavir 
 
HIV protease inhibitors include quite distinct compounds with many cell 
effects that account for their broad antitumor activity. The molecular 
mechanisms underlying anticancer activity of different HIV-PIs are summarized 
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in  table 1. 
 
 
Table 1. HIV-protease inhibitors and their proposed mechanisms of action CDK: Cyclin-
dependent kinases; HIF-1α: Hypoxia-inducible factor 1-alpha; MMP: Matrix metallo-
proteinases; MRP-1: Multidrug resistance- associated protein-1; NFkB: Nuclear Factor-
KappaB; VEGF: Vascular endothelial growth factor. 
 
Among these drugs, nelfinavir is considered the most potent antitumor 
HIV-PIs (Chow et al. 2006; Yang et al. 2006b; Gills et al. 2007), although its 
toxicity and side effects limit its use as antitumoral drug (Carr et al. 1998; Hui 
2003; Koster et al. 2003; Ben-Romano et al. 2004; Reyskens and Essop 2014). 
The antitumoral effects of nelfinavir have been  related to several mechanisms 
of action: inhibition of matrix metalloproteinase (MMP)-2; induction of 
endoplasmatic reticulum (ER) stress; inhibition of proteasome function and 
Nuclear factor kappa B (NfkB) activity; inhibition of Akt phosphorylation; and 
induction of autophagy (Pajonk et al. 2002; Monini et al. 2003; Yang et al. 
2006b; Toschi et al. 2011). As the downregulation of akt pathway represents the 
main molecular mechanism underlying nelfinavir anti-proliferative activity, it 
will be discussed in a dedicated chapter. 
One of the most analysed antitumor mechanism of action for nelfinavir is 
the induction of ER stress (Gills et al. 2007; Pyrko et al. 2007). ER has a 
fundamental role in the synthesis of surface and secreted proteins, their 
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assembly and folding; thanks to its oxidative environment that is critical for 
formation of disulfide bonds (Schroder and Kaufman 2005). Alterations of ER 
functions can determine ER stress, that elicits the activation of the unfolded-
protein response (UPR), a cell protective mechanism, resulting in transient 
induction of cell cycle arrest and accumulation of molecular chaperons to bind 
and recover unfolded proteins. Prolonged exposure of cells to ER stress or cell 
cycle arrest can induce a switch from cell survival to caspase dependent 
apoptosis (Kaufman 2002; Xu et al. 2005). Nelfinavir activates the 
endoplasmic reticulum stress–UPR pathway in different tumor types such as 
breast cancer, ovarian cancer, non-small-cell lung carcinoma and glioma cells 
(Pyrko et al. 2007; Bruning et al. 2009; Bruning et al. 2010; Thomas et al. 
2012). As part of UPR, global protein synthesis decreases and DNA damage 
inducible protein (GADD34) are induced by acting as a phosphatase in 
complex with protein phosphatase 1. This complex can dephosphorilate akt, 
determining double anti-cancer effect of nelfinavir in tumoral cells (Gupta et al. 
2007). 
The induction of ER stress coud be dependent by inibition of proteasome 
activity. The proteasome controls protein turnover, clearance of misfolded 
proteins, apoptosis, degradation of tumor-suppressor gene products, the 
function of cyclin-dependent kinase (CDK) inhibitors, and the proteolytic 
maturation and activation of the transcription factor NF-kB. The inhibition of 
the proteasome leads to excessive accumulation of misfolded proteins in the 
endoplasmic reticulum and activates UPR. It has been demonstrated that 
nelfinavir inhibits 26S chymotrypsin-like proteasome activity and promotes 
apoptosis in myeloma cell lines by inducing UPR pathway (Bono et al. 2012). 
Moreover, nelfinavir used in combination with a proteasome inhibitor 
bortezomib enhances proteotoxicity in non-small-cell-lung carcinoma 
(NSCLC) and multiple myeloma (Kawabata et al. 2012). Nevertheless, the 
hypotesys of  nelfinavir mediated inhibition of proteasome activity was not 
supported in all studied tumor types: indeed, in the original report of 1998 
(Andre et al. 1998) and in more recent work (Jiang et al. 2007b), nelfinavir 
does not affect the chymotrypsin-like activity of 20S proteasome even at a high 
concentration (100μM).    
Autophagy is a process in which intracellular membrane structures 
sequester proteins and organelles to degrade and turn over these materials 
under conditions of stress, starvation, or inhibition of the phosphatidylinositol-
3-kinase (PI3K)–Akt-mammalian target of rapamycin pathway (Pyrko et al. 
2007; Levine and Kroemer 2008). The role of autophagy has been investigated 
in nelfinavir-mediated cell effects and it has been demonstrated that this drug 
can induce autophagy. The  induction of autophagy counteracts the cytotoxicity 
of nelfinavir, because inhibition of autophagy with 3-methyladenine (a small- 
molecule inhibitor of autophagy) increased nelfinavir-induced death (Gills et al. 
2007). 
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Nelfinavir regulation of AKT pathway 
 
Akt or Protein Kinase B (PKB) is a serine/threonine protein kinase that 
functions as a critical regulator of cell survival and proliferation. In mammals 
three akt isoforms (akt1,akt2,akt3) have been identified with the same 
conserved domain structure: an amino terminal pleckstrin homology (PH) 
domain, a central kinase domain and a carboxyl-terminal regulatory domain 
with hydrophobic motif. All akt isoforms except akt3 contain two regulatory 
phosphorylation sites, Thr-308 in the activation loop within the kinase domain 
and Ser-473 in the C-terminal regulatory domain (Song et al. 2005). Akt 
signaling cascade starts with the activation of PI3K following cross-linking of a 
growth factor with its surface tyrosine kinase receptor. Active PI3K 
phosphorylates membrane bound phosphoinositidies, thus converting 
phosphatidylinositol (4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) (Coffer et al. 1998; Chan et al. 1999; Yuan and Cantley 
2008). Akt interacts with PIP3 through PH domain, and moves to the inner cell 
surface where it can be phosphorilated on Thr-308 by the phosphoinositide-
dependent kinase1 (PDK1). Although phosphorylation at Thr-308 partially 
activates akt, full activation requires Ser-437 phosphorylation by mammalian 
target of rapamycin complex 2 (mTORC2) (Shiota et al. 2006; Yang et al. 
2006a) or by akt autophosphorylation (Chan and Tsichlis 2001). PIP3 levels are 
tightly regulated by the action of phosphatases PTEN, an important negative 
regulator of PI3K/akt signaling (Cantley and Neel 1999; Di Cristofano and 
Pandolfi 2000). Other negative regulators of akt signaling include phosphatases 
PP2A that preferentially dephosphorylate akt on the Thr-308 but also on the 
Ser-473 and phosphatases PHLPP that specifically dephosphorylate on Ser-473 
(Liao and Hung 2004; Brognard et al. 2007). 
Following phosphorylation, activated akt phosphorylates many substrates, 
which control important cell processes such as cell cycle progression, 
apoptosis, transcription and translation, summarized in figure 4 (Ahmed and 
Davies 2011).  
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Figure 4. Akt regulates many intracellular processes through phosphorylation of different 
targets Following surface receptors activation, PI3k induces akt activation. phosphorylation of 
akt  promotes cell proliferation by activation of mTOR and cyclin D by GSK-3 inhibition and 
blocks apoptosis through MDM2/p53 and Bad regulation. 
 
Akt activation affects cell cycle progression, through regulation of cyclin 
D stability (Muise-Helmericks et al. 1998) and inhibition of cell cycle negative 
regulators such as p27 (Collado et al. 2000) and p21 (Zhou et al. 2001). Akt can 
also regulate nucleo-cytoplasmic localization of critical substrates involved in 
cell cycle and apoptosis. In particular, phosphorylation by akt is necessary for 
nuclear translocation of Mouse double minute 2 homolog (Mdm2). It has been 
reported that when Mdm2 is restricted to the cytoplasm it is degraded (Mayo et 
al. 2002). After growth factor stimulation, Mdm2 is phosphorylated by akt and 
enters the nucleus, leading to reduction of both p53 levels and transactivation 
(Mayo and Donner 2001). To prevent apoptosis, akt phosphorylates and 
inactivates the pro-apoptotic factors BAD and pro-caspase 9, inhibing the 
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release of cytochrome c from mitochondria (Datta et al. 1997; Cardone et al. 
1998). Akt also phosphorylates and inactives different kinases upstream stress-
activated protein kinase (SAPK) leading to inhibition of SAPK-mediated 
apoptosis (Kim et al. 2001). Moreover, akt activates Ikb kinase, a positive 
regulator of NF-kB, and increases transcriptional activation of CREB  which 
results in transcription of anti-apoptotic genes such as Bcl-2 (Wang et al. 1999; 
Burgering and Medema 2003). However, the major physiological function of 
akt is the regulation of cell metabolism. In particular, Akt phosphorylates and 
inactivates glycogen synthase kinase 3, thus stimulating glucose utilization 
(Cross et al. 1995). Akt also regulates protein synthesis through mammalian 
target of rapamycin complex 1 (mTORC1), a protein complex that functions as 
a nutrient/energy/redox sensor. mTORC1 activates transcription and translation 
through its interactions with p70-S6 Kinase 1(S6K1) and 4E-BP1, the 
eukaryotic initiation factor 4E (eIF4E) binding protein 1 (Hay and Sonenberg 
2004). Akt regulates mTORC1 through direct phosphorylation of tuberous 
sclerosis complex-2 (TSC2) and proline-rich akt substrate 40 kDa (PRAS40), 
proteins that suppress mTORC1 kinase activity and thereby activate mTORC1 
(Dunlop and Tee 2009; Huang and Manning 2009). Under certain physiological 
or pathophysiological conditions, akt protein can be degraded by the ubiquitin 
proteasome-dependent pathway, caspase-mediated cleavage, and caspase-
dependent ubiquitination (Liao and Hung 2010). Akt stability are regulated by 
Hsp90, an important molecule chaperone which acts in cooperation with cdc37 
to stabilize akt and prevent akt from PP2A-mediated inactivation (Hanada et al. 
2004). Among molecule chaperones, Hsp90 is of prime importance to the 
survival of cancer cells, since the list of Hsp90 client proteins includes key 
components of multiple signaling pathways utilized by cancer cells for growth 
and/or survival (Neckers and Ivy 2003; Neckers and Neckers 2005). 
Detachment of akt from the Hsp90/cdc37 complex increases akt sensivity to 
PP2A-mediated dephosphorylation and results in ubiquitination and 
degradation of akt via proteasome. It is not yet clear under what patho-
physiological conditions will the ubiquitin proteasome pathway recycle or 
degrade Hsp90-bound akt (Sato et al. 2000; Georgakis and Younes 2005; 
Powers and Workman 2006). Another mechanism to regulate akt folding and 
stability is the phosphorylation of particular Thr-Pro motifs on Thr-92 and Thr-
450 which in turn promotes the interaction of akt with Pin1, a peptidyl-prolyl 
cis/trans isomerase required for the maintenance of akt stability and activation 
phosphorylation (Liao and Hung 2010). 
The signaling crosstalks involving akt determine its role in the 
development of cancers possibly through effects on cell proliferation, adhesion, 
migration, invasion, apoptosis, and angiogenesis. Cancer genomic analyses 
have revealed that multiple components of the PI3K/akt pathway are frequently 
mutated or altered in common human cancers (Wood et al. 2007), underscoring 
the importance of this pathway in cancer. In addition, akt activation promotes 
resistance to chemotherapy as well as radiation therapy (Tsurutani et al. 2007). 
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For these reasons the inhibition of akt pathway should offer some selectivity in 
the treatment of many cancers. 
Several groups (Gupta et al. 2005; Yang et al. 2006b; Cuneo et al. 2007) 
suggested that inhibition of PI3K-induced activation of akt by HIV-PIs is an 
important mechanism by which these drugs exert anti-tumor effect. Moreover,  
PIs-mediated decreased phosphorylation of akt  correlates with increased 
sensitivity to ionizing radiation and chemotherapy (Gupta et al. 2005; Yang et 
al. 2006b; Cuneo et al. 2007). Yang and colleagues (2006) demonstrated  that 
nelfinavir inhibits growth and induces apoptosis in cell lines of prostate cancer, 
via disrupted signal transducer and activator of transcription 3 (STAT3) 
signalling. The same investigators also showed similar proapoptotic effects in 
NSCLC via upregulation of p53 and the cyclin-dependent kinase inhibitors p21 
and p27 and downregulation of Bcl-2 and MMP2. All these effects might be 
mediated through inhibition of Akt phosphorylation, as forced expression of 
constitutively active Akt partly reverses the nelfinavir-mediated growth 
inhibition. It has been suggested that akt inactivation could be related to block  
of akt translocation to plasma membrane, where it is phosphorylated by PDK1 
and mTORC2 kinases (Ben-Romano et al. 2004). Nelfinavir could also act 
upstream of the akt signaling pathway by inhibition of tyrosine kinase receptor 
activation (Gills et al. 2007). However, Nelfinavir-mediated inhibition of Akt 
phosphorylation reduce in vitro tumoral cell proliferation and sensityzed tumor 
cells to chemotherapy and radiotherapy. Indeed, nelfinavir can be used in 
combination with chemoradiation for locally advanced rectal cancer (Buijsen et 
al. 2013), glioblastoma (Jiang et al. 2007c), head and neck carcinoma and non-
small-cell lung carcinoma (Pore et al. 2006; Rengan et al. 2012). Another 
possible explanation for the efficacy of combinatorial approach in cancer 
therapy has been given by Fukuda et al. (2013). In this study, they demonstrated 
that nelfinavir interacts with multidrug resistance protein 4/ATP binding 
cassette transporter 4 (MRP4/ABCC4) and regulates its substrate-stimulated 
ATPase activity, thus increasing its own antitumor efficacy as well as cancer 
chemotherapeutics (Fukuda et al. 2013). It has been reported that also 
saquinavir and amprenavir but not indinavir or ritonavir inhibit akt 
phosphorylation in different tumor types: H-ras mutated bladder cancer, 
epidermal growth factor receptor mutated head and neck cancer, and K-ras 
mutated pancreatic cancer and lung cancer cell lines (Gupta et al. 2005). This 
resulted in radiosensitisation of these tumors in vitro and in vivo in a nude-
mouse model. 
 Nelfinavir does not decrease phosphorylation of Akt in normal cells 
and/or radiosensitise them, thus suggesting drug selectivity for malignant cells 
(Jiang et al. 2007c). In addition, the kinetics of akt inhibition are cell line 
specific and do not correlate with other nelfinavir biological effects such as ER 
stress and autophagy (Gills et al. 2007). 
Therefore, akt inactivation is not a general molecular mechanism at the 
basis of nelfinavir anti-tumoral activity, since this phenomenon has not been 
19 
 
confirmed in all tumor types. Indeed, nelfinavir does not affect akt activity in 
particular breast carcinoma cell lines (Bruning et al. 2010) and in melanoma 
cells (Jiang et al. 2007b).  Although there are exceptions, the inhibition of  Akt 
signaling remains one of the main antitumor mechanisms of nelfinavir.  
  
Nelfinavir in Breast Cancer 
 
Breast cancer is the most frequent cancer in the female population. It 
comprises 22,9% of invasive cancers in women and 16% of all female cancers 
(http://www.who.int/cancer/detection/breastcancer/en). Despite recent 
advances in chemotherapy, recurrent or metastatic breast cancer patients have a 
median survival of 20 months. There are many risk factors known to increase 
the occurrence of breast cancer: female sex, older age, genetics, lack of 
childbearing or lack of breastfeeding, higher levels of some hormones, specific 
dietary patterns, and obesity (McPherson et al. 2000; Reeder and Vogel 2008). 
How these risk factors contribute to the transformation of normal cells 
into cancer cells remains incompletely understood. Many evidence suggests 
that genetic alterations, including both inherited and acquired mutations of 
specific tumor suppressors and oncogenes, represent the primary cause of 5-
10% of all cases (Gage et al. 2012). For example, inherited mutations in Breast 
Cancer (BRCA) tumor suppressors confer more than 50% higher risk for 
women to develop breast cancer. Women with inherited BRCA1 or BRCA2 
gene mutations also have an increased risk of ovarian cancer (Chen and 
Parmigiani 2007). More than 70% of breast cancer cases with BRCA mutations 
have also mutated p53 gene  resulting in a doubling of breast cancer 
occurrence. However, mutations in BRCA genes account for only 2 to 3 percent 
of all breast cancers (Wooster and Weber 2003). The specific characteristics of 
the cancer determine the treatment, which may include surgery, hormonal 
therapy, chemotherapy, radiation and/or immunotherapy (Florescu et al. 2011). 
Breast cancer is usually classified primarily by its histological appearance. 
Most breast cancers are derived from the epithelium lining the ducts or lobules, 
and these cancers are classified as ductal or lobular carcinoma. Breast cancers 
are classified also by grade of differentiation, stage, receptor status and genetic 
alterations (Yerushalmi et al. 2009). Receptor status is defined by the presence 
of three important receptors: estrogen receptor (ER), progesterone receptor 
(PR), and HER2. 
ER positive cancer cells depend on estrogen for their growth, so they can be 
treated with endocrine therapy that blocks estrogen effects by affecting receptor 
binding with antagonists such as tamoxifen or by depriving the tumor from 
estrogen by aromatase inhibitors. Older endocrine therapies are based on high 
dose of estrogens and androgens, and work by less well-known mechanisms, 
although it has been proposed that high-dose estrogen can induce apoptosis by 
activationing intrinsic and exstrinsic pathways (Lewis-Wambi and Jordan 
2009). Endocrine therapy is the most effective treatment for ER-positive breast 
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cancer, but its effectiveness is limited by high rates of de novo resistance and 
resistance acquired during treatment. The mechanisms responsible for 
endocrine resistance include the loss of ER expression and activation of escape 
pathways such as HER2 pathway, that can provide tumors with alternative 
proliferative and survival stimuli (Osborne and Schiff 2011). 
 Approximately 25%-30% of human breast cancers overexpress HER2 
and tend to be more aggressive and less responsive to hormone treatments than 
other types of breast cancer. This type of cancer is treated with trastuzumab, a 
monoclonal antibody that interferes with HER2, and lapatinib, a dual inhibitor 
of HER2 and EGFR tyrosine kinases that is used in combination with 
chemotherapeutic agent capecitabine (Goldenberg 1999; Geyer et al. 2006). 
Cells that do not have any of these three receptor types (estrogen receptors, 
progesterone receptors, or HER2) are called triple-negative, and can be treated 
only with chemotherapy which destroys fast-growing cancer cells with serious 
side effects on normal cells. Even within these major types of breast cancer, 
individual tumors appear to be driven by their own sets of genetic changes, that 
affect anticancer treatment efficiency. To overcome this problem, many other 
drugs that inhibit different targets could be useful for therapy. An important 
target in breast cancer research is represented by PI3K/akt pathway, as it is 
frequently aberrantly activated in breast cancer occurring in up to one quarter of 
breast cancers (Baselga 2011). The majority of mutations are in PIK3CA, 
encoding the catalytic p110α subunit of PI3K, and the proportion of breast 
tumors exhibiting mutations in PI3K is in the range of 20%–25%, depending 
on the breast cancer subtype. For example, in ER–positive tumors, these 
mutations occur in >30% of cases. Also, in HER2 positive disease, mutations 
are evident in about one quarter of tumors. Meanwhile, it seems that mutations 
in triple-negative breast cancer may be less frequent (Stemke-Hale et al. 2008). 
It has been demonstrated that PI3K mutations play a role in resistance to some 
of the therapies that block upstream tyrosine kinase receptors such as anti-
HER2 agents. Current PI3K inhibitors under development are grouped by their 
specificity, ranging from pure PI3K inhibitors, to compounds that block both 
PI3K and mTOR (dual inhibitors), to pure catalytic mTOR inhibitors, and to 
inhibitors that block Akt. Among these, anti-mTOR agents have clinical 
activity against breast cancer, but activation of feedback loops may result in 
decreased efficacy (Baselga 2011). In this context, novel inhibitors directed to 
different cell targets and affecting breast cancer cell growth and survival, may 
potentially improve the efficacy of therapy and the survival rate. There are few 
evidences that nelfinavir exerts an anti-proliferative effect in breast cancer, but 
the mechanisms by which nelfinavir may be involved in cancer inhibition are 
not well understood. 
It has been demonstrated that nelfinavir affects breast cancer cell viability 
by inducing endoplasmic reticulum stress and autophagy (Bruning et al. 2010). 
ER stress and autophagy are related: many agents that cause ER stress lead to 
increased autophagic activity; conversely, there are indications that blockage of 
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autophagy increases ER stress. There are evidences that induction of ER stress 
with simultaneous inhibition of autophagy lead to efficient killing of triple  
negative breast cancer in vitro and in vivo. For this reason, when nelfinavir is 
used in combination with inhibitors of autophagy, the killing of cancer cells is 
potentiated (Thomas et al. 2012). 
The involvement of akt signalling and proteasome activity in nelfinavir-
mediated effects has been questioned and could be related to the analyzed cell 
lines. Several studies have shown that ER stress induces activation of akt 
signaling, which primarily represents a short-term effect whereas prolonged 
exposure of cells to ER stress induces akt inactivation (Hosoi et al. 2007; Dai et 
al. 2009). This indicates that the downregulation of akt phosphorylation is a 
secondary event. As above mentioned, the downregulation of akt 
phosphorylation is an important mechanism of nelfinavir to inhibit cell growth 
in several tumor types such as advanced pancreatic cancer, malignant glioma, 
head and neck carcinoma, and advanced rectal cancer, leading to increased 
sensitivity to radiation (Gupta et al. 2007; Pyrko et al. 2007; Brunner et al. 
2008; Buijsen et al. 2013). In breast cancer there are contrasting data regarding 
the nelfinavir-mediated inhibition of akt pathway. A recent study demonstrated 
that nelfinavir affects not only akt phosphorylation but also reduces akt total 
protein expression levels (Shim et al. 2012). The authors suggested that akt 
downregulation is mediated by the inhibition of HSP90 chaperon activity 
resulting in degradation of HSP90 client proteins. These proteins are HER2, 
akt, Epidermal Growth Factor Receptor (EGFR), Hypoxia Inducible Factor-1α 
(HIF-1α), androgen receptor, Bcr-Abl, and CDKs, that are key players of cancer 
cell survival and proliferation. Therefore the indirect inhibition of HSP90 
function by nelfinavir can cause simultaneous inhibitory effects on multiple 
pathways of cancer cell signaling. Because of the large number of signaling 
proteins affected, nelfinavir could overcome the drug resistance which can 
occur during treatment with trastuzumab and lapatinib (Berns et al. 2007) that 
is generally due to mutation in PI3K gene. However, the modality of interaction 
between nelfinavir and HSP90 remains to be further elucidated using such 
techniques as x-ray crystallography.  
Another molecular mechanism analyzed in nelfinavir treated breast cancer 
is the proteasome inhibition. This mechanism seems to be cell line specific, 
since nelfinavir exerts no significant effect on the chymotryptic proteasome 
activity in HER2 negative breast cancer cell models (Bruning et al. 2010) while 
it inhibit 20S proteasome chymotrypsin-like activity in HER2 positive breast 
cancer cells (Shim et al. 2012). However, the inhibition of proteasome in HER2 
positive breast cancer cells does not explain the effects of nelfinavir on akt 
pathway, since classical proteasome inhibitors  do not reduce akt protein levels. 
Furthermore, proteasome inhibitors prevent certain nelfinavir effects thus 
suggesting that proteasome is not the relevant target for nelfinavir.  
In conclusion, nelfinavir exerted pleiotropic biochemical and cell effects 
that included induction of endoplasmic reticulum stress, autophagy, and 
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apoptosis but the molecular mechanism at the basis of these anti-tumoral 
effects as well as akt downregulation is still unknown. 
To date nelfinavir is in clinical trial for several cancers such as rectal 
cancer, solid tumors, multiple myeloma, cervical cancer, pancreatic cancer, non 
small cell lung carcinoma, glioblastoma, renal cell cancer, cancers of the head 
and neck, liposarcomas (http://www.cancer.gov/clinicaltrials) further 
investigations are necessary to identify all molecular targets and to exend the 
treatment to breast cancer.  
It was established that the nelfinavir maximum plasma concentration of 3-
4mg/l  in HIV-infected patients patients (Tebas and Powderly 2000) is also able 
to inhibit tumoral cell growth. However, it has been reported that in HIV-
positive patients, long-term treatment with nelfinavir at therapeutic 
concentrations can trigger metabolic side-effects that resemble the metabolic 
syndrome, a combination of risk factors that predispose to future onset of type 
2 diabetes mellitus and cardiovascular disease (Reyskens and Essop 2014). For 
this reason also the use of HIV-PIs as anticancer agents could be limited by  
these side effects. There are several mechanisms whereby HIV-PIs can exert 
their detrimental effects, however, it has been proposed that drug-induced 
generation of oxidative stress and associated downstream targets play a central 
role in this process. Indeed, the link between HIV-PIs usage and increased 
reactive oxygen species (ROS) production is well established by several cell 
studies, including macrophages (Wang et al. 2007), cardiomyocytes (Deng et al. 
2010), beta cells (Chandra et al. 2009); endothelial cells (Mondal et al. 2004), 
skeletal muscle cells (Touzet and Philips 2010), adipocytes (Ben-Romano et al. 
2006), porcine arteries and aortas in an atherogenic mouse model (Conklin et 
al. 2004; Chai et al. 2005).  
To date, It has not been reported a PIs-mediated induction of ROS in 
tumor cells and the role of ROS as players in the molecular mechanism 
underlying anti-cancer effects of these drugs has not been investigated. 
 
1.3 INVOLVEMENT OF ROS IN CANCER THERAPY 
 
ROS 
 
ROS consist of radical and non-radical oxygen species formed by the 
partial reduction of oxygen (Halliwell 1996; Fridovich 1999). Some of the most 
common ROS are superoxide anion, hydrogen peroxide and the higher reactive 
hydrogen radical. Superoxide radical anion derives from molecular oxygen by 
the addition of an electron, and has a short lifetimes in the cell as it quickly 
reacts with antioxidants or transform to hydrogen peroxide through 
spontaneous or enzyme catalysed reaction. Different from superoxide anion, 
hydrogen peroxide can penetrate biological membranes. It plays a radical 
forming role as an intermediate in the production of more reactive ROS 
molecules such as hydroxyl radical via oxidation of transition metals. Due to its 
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strong reactivity with biomolecules, hydroxyl radical is capable of doing more 
damage to biological systems than any other ROS (Betteridge 2000). ROS 
production is a natural process of normal cells. The formation of superoxide 
takes place spontaneously, especially in the mitochondria through the oxidative 
phosphorylation process that occur during aerobic respiration. Superoxide is 
also produced endogenously by lipoxygenase, cyclooxygenase, and 
flavoenzymes such as NADPH-oxidase and  xantine-oxidase (Nordberg and 
Arner 2001). Although the majority of ROS production originates from 
mitochondria, generated by respiratory chain complex I and III, matrix 
dehydrogenases and mono-amine oxidase (Muller et al. 2004; Zorov et al. 
2006), NADPH-oxidases represent key modulators that generate highly 
regulated amounts of superoxide anion by electron transfer from NADPH to 
molecular oxygen (Meitzler et al. 2013). Hydrogen peroxide can be generated 
directly by some oxidoreductases, but most hydrogen peroxide production 
results from the dismutation of superoxide anion (Forman 2007). Nitric oxide 
(NO) is considered another member of the free radical family for its capability 
to easily react with other free radicals, generating less or more reactive 
molecules. It has been demonstrated that NO acts both as anti-oxidant and 
oxidant molecule, because it can inhibit lipid peroxidation in  cell membranes 
(Hogg and Kalyanaraman 1998; Rubbo et al. 2000) but it can react with anion 
superoxide to produce peroxynitrite, which is highly cytotoxic (Beckman and 
Koppenol 1996). Peroxynitrite may react directly with different biomolecules 
in one- or two-electron reactions, readly react with CO2 to form highly reactive 
nitroso peroxocarboxylate, or protonated as peroxonitrous acid undergo 
homolysis to form either hydroxyl radical and nitrogen dioxide or rearrange to 
nitrate. NO is synthesized enzymatically from L-arginine by NO synthase 
(NOS)(Beck et al. 1999; Bredt 1999). The complex enzymatic catalysis of NOS 
involves the transfer of electrons from NADPH, via the flavin FAD and FMN 
in the carboxy-terminal reductase domain, to the heme in the amino-terminal 
oxygenase domain, where L-arginine is oxidized to L-citrulline and NO. There 
are three main isoforms of the enzyme which differ in their expression and 
activities: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS 
(eNOS)(Beck et al. 1999; Bredt 1999). 
A common feature among the different  ROS types is their capacity to 
cause oxidative damage to DNA, lipids, and proteins (Marnett 2000; Stadtman 
and Levine 2000). In particular, ROS can react with DNA leading to oxidation 
of purines, DNA-protein cross links, and cleavage of DNA. If these alterations 
are not rapidly repaired, cells can accumulate DNA mutations promoting 
cancerogenesis or cell-death. Polyunsaturated fatty acids as well as several 
amino acid residues are other targets for free radical attacks. The oxidative 
modification of proteins results in changes in structure and/or function of the 
protein, and has been recognized as playing a role in the progression of several 
pathophysiologic processes (Dean et al. 1997). These cytotoxic effects of ROS 
explain the evolution of complex arrays of nonenzymatic and enzymatic 
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detoxification mechanism (Decker and Muller 2002). The antioxidant enzyme 
systems include superoxide dismutase (SOD), superoxide reductase (SOR), 
catalase, peroxiredoxin, thioredoxin, and glutathione peroxidase. SOD was the 
first ROS-metabolizing enzyme discovered (McCord and Fridovich 1969) and 
consist of three forms with different intracellular localization: cytosolic 
(SOD1), mitochondrial (SOD2) and extracellular (SOD3) (Nordberg and Arner 
2001). These isoforms differ also in metal co-factor; SOD1 and SOD3 use 
copper and zinc while SOD2 uses manganese to fulfill to their functions. The 
role of all three forms of SOD is to catalyze the formation of hydrogen 
peroxide from superoxide. Although not as reactive as superoxide, hydrogen 
peroxide induces cell damage by conversion into hydroxyl radical via the 
Fenton-reaction catalyzed by copper or iron ions (Fridovich 1999; Halliwell 
1999). Thus, another enzyme, catalase, transforms hydrogen peroxide into 
molecular oxygen and water, lowering the risk of 
 
hydroxyl radical formation. 
However, it is likely that the major hydrogen peroxide-removing enzymes in 
mammalian cells are the glutathione peroxidase, which contain selenium in 
their active site and are involved not  only in hydrogen peroxide removal, but 
also in the metabolism of lipid peroxides. Reduced glutathione, the substrate of 
glutathione peroxidase, may additionally exert direct antioxidant effects. ROS 
formation and metabolism can be summarized as shown in figure 5. The 
oxidative status of the cell is the primary factor regulating gene expression and 
activity of these enzymes (Rodriguez et al. 2004). 
A large number of low molecular weight compounds are considered to be 
antioxidants of biological importance, including vitamins C and E, different 
selenium compounds, lipoic acid, and ubiquinones (Nordberg and Arner 2001).  
Therefore the role of cellular antioxidant  systems is to protect cells and 
organisms from the lethal effects of excessive ROS formation. When ROS 
overcome cell antioxidant defense system, through both an increase in ROS 
levels and a decrease in the cellular antioxidant capacity, oxidative stress 
occurs (Ray et al. 2012). Cells often tolerate mild oxidative stress by 
upregulating synthesis or activity of antioxidant defense systems in an attempt 
to restore the balance (Veal et al. 2007). However, severe oxidative stress 
produces DNA damage, rises in intracellular free Ca
2+
 and iron, proteins 
damage (including membrane ion transporters), and lipid peroxidation, leading 
to cell injury (Alfadda and Sallam 2012). 
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Figure 5. ROS formation and metabolism Molecular sources of superoxide anion (O2), are 
represented by flavin-containing enzymes and mitochondrial oxidative phosphorylation. 
Hydrogen peroxide (H2O2) and hydroxyl radicals (
.
OH) are generated through superoxide anion  
and H2O2 reduction/oxidation reactions by anti-oxidant enzymes such as SOD, glutathione 
peroxidase (GSH), catalase and peroxiredoxin (Prx). A massive ROS production determines 
lipid peroxidation and DNA and protein damages. 
 
ROS have not only a negative role in cell. While an excessive production 
of ROS leads to cell-damage, regulated ROS production is indispensable for 
several biological function such as cell growth (Foreman et al. 2003), 
differentiation (Li et al. 2006), apoptosis (Cai 2005) by regulating different 
intracellular pathways. Indeed, ROS are involved  in immune defense, 
antibacterial action, vascular tone (Alfadda and Sallam 2012). Moreover, ROS 
are used as secondary messengers in the intracellular signal transduction by 
several cytokines, growth factors, hormones, and neurotransmitters (Thannickal 
and Fanburg 2000). Indeed, ROS show the essential characteristics of second 
messenger: increases in their concentration occur through enzymatic 
generation; decreases in their concentration occur through enzymatic 
degradation catalyzed by catalase, glutathione peroxidase and peroxiredoxins; 
their intracellular concentration rises and falls within a short period; and they 
are specific in action (Forman 2007). 
Cellular ROS sensing and metabolism are tightly regulated by a variety of 
proteins involved in the reduction/oxidation mechanism. The main molecular 
mechanism through which ROS and NO directly interact with critical signaling 
molecules consists of redox regulation of redox-reactive cysteine residues on 
proteins. Generally, any protein containing a deprotonated cysteine residue is 
susceptible to oxidation by ROS. The cysteine residues of most cytosolic 
proteins are protonated, due to the low pH of the cytosol, and therefore unable 
to react with sense hydrogen peroxide. It is thus an essential feature of most 
hydrogen peroxide sensor proteins that they contain cysteine residues with a 
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low pKa that make more susceptible to oxidation (Veal et al. 2007). 
Oxidation of these residues forms reactive sulfenic acid that can form 
disulfide bonds with nearby cysteines or undergo further oxidation to sulfinic 
or sulfonic acid. The attachment of nitrosonium ion (NO
+
) to cysteine 
sulfhydryls defined protein S-nitrosylation, emerged recently as a prototype  of 
redox-dependent post-translational modifications (Stamler et al. 2001), which 
mediate a number of actions of the NO group in various biological processes 
(Stamler et al. 2001; Gow et al. 2002). Recently, protein S-
nitrosylation/denitrosylation has been recognized as a regulatory component of 
signal transduction comparable with phosphorylation/ dephosphorylation 
(Mannick and Schonhoff 2002; Liu et al. 2004). 
ROS, especially hydrogen peroxide, can also interfere with other post-
transcriptional modifications such as sumoylation, thus regulating localization, 
activity and stability of many proteins. It has been demonstrated that hydrogen 
peroxide at lower concentration inhibits conjugation of SUMO to proteins, 
while at higher concentrations causes an increase of sumoylation levels in 
proteins (Manza et al. 2004; Zhou et al. 2004). Therefore, exposure to ROS 
leads to reversible oxidation of thiol groups of key cysteine residues in many 
proteins, including transcriptional regulators, kinases, phosphatases, structural 
proteins, metabolic enzymes, and SUMO ligases (Veal et al. 2007). These 
oxidative modifications result in changes in structure and/or function of 
proteins and enzymes (Ray et al. 2012). 
Through oxidative modification, ROS production promotes the activation 
of many intracellular pathways involved in cell survival and proliferation. In 
particular ROS activates Mitogen-activated protein kinases (MAPK) cascade 
by direct activating-oxidation of several kinases, or by inhibiting-oxidation of 
related phosphatases. In the same way, ROS regulate PI3K pathway, thus 
playing a key role in cell proliferation. Hydrogen peroxide oxidizes and 
inactivates PTEN phosphatase through disulfite bond formation, leading to 
activation of the PI3K pathway. Furthermore, through upregulation of tyrosine 
kinases activity, low levels of hydrogen peroxide can regulate the activity of 
antioxidant enzyme. High levels of ROS can directly oxidize these enzyme thus 
modulating their activity or inducing their degradation (Veal et al. 2007). 
ROS are also able to modulate transcription factor activity via decreased 
binding to promoter regions through different mechanisms: via oxidative 
damage to the DNA (Ghosh and Mitchell 1999), or more directly by redox 
regulation of transcription factor activation (Allen and Tresini 2000) and/or 
altered DNA binding due to redox-induced modification of the transcription 
factor protein (Abate et al. 1990; Marshall et al. 2000). Redox regulation of 
transcription factors is important in determining gene expression profile and 
cell response to oxidative stress. Some of the most important transcription 
factors involved in the response to oxidative stress are activator protein 1(AP-
1), p53, NFkB, hypoxia inducible factor-1 (HIF-1α) and nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2), that are all modulated by redox regulation 
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of  redox factor-1(Ref-1). The transcriptional regulatory function of Ref-1 is 
mediated through its redox activity on above mentioned transcription factors. A 
particular cysteine residue in N terminus region of Ref-1 is required for the 
reduction and increased DNA binding of targeted transcription factors. Ref-1 
was shown to be upregulated by genotoxic agents and oxidants, and protect 
cells from DNA and oxidative damage inducing the transcription of antioxidant 
detoxification genes. ROS are also involved in DNA damage response  through 
ataxia-telangiectasia mutated (ATM) pathway. Indeed, hydrogen peroxyde is 
able to activate ATM not through DNA damage but through formation of active 
ATM dimers via intermolecular disulfite bond (Ray et al. 2012). 
 In conclusion, “oxidative regulation” better describes the action of ROS, 
since ROS modulate physiological processes but are also involved in many 
pathological situations. Therefore, according to their nature, quantity, source, 
and production kinetics in the cell, ROS differently affect cell regulation. 
 
ROS as pro-tumoral or anti-cancer factors 
 
It has been demonstrated that ROS promote a number of cancers. This 
phenomenon can be explained primarily by the ROS ability to induce DNA 
damage enhancing the rate of tumor-causing mutations and genetic instability, 
and by their pro-inflammatory effects (Alfadda and Sallam 2012). Another 
aspect of ROS protumoral effects is that they are able to provoke uncontrolled 
cell growth by overstimulation of Mitogen-activated protein kinases (MAPK) 
signal transduction pathways (Kulisz et al. 2002). Furthermore, ROS can 
activate hypoxia induced factor 1 (HIF-1) that stimulates the cells to gain 
energy from glucose under hypoxic conditions. HIF-1 increases the expression 
of glycolysis enzymes and additionally stimulates the development of new 
blood vessels by increasing the expression of angiogenic factors such as 
Vascular Endothelial Growth Factor (VEGF) to enhance oxygen supply (Gao et 
al. 2007). Therefore, ROS promote cell damage that may be advantageous to 
cancer cell growth. Indeed, ROS can induce both genomic instability and 
alterations in cell signaling processes related to survival, proliferation, 
resistance to apoptosis, angiogenesis and metastasis, thus contributing to cancer 
initiation, promotion and progression. Accordingly, antioxidants could be able 
to decrease tumorigenesis by neutralizing the deleterious effects of ROS 
(Sablina et al. 2005; Reliene and Schiestl 2006). Many studies have shown a 
different point of view regarding the link between ROS and cancer, pointing 
out ROS production as an effect of tumoral transformation. Indeed, it has been 
well established that cancer have a greater concentration of endogenous ROS 
than normal cells (McEligot et al. 2005; Lu et al. 2007; Hoyt et al. 2011). 
Several works have reported a presence of markers of constitutive oxidative 
stress in samples from in vivo breast carcinoma (Toyokuni et al. 1995; Portakal 
et al. 2000; Brown and Bicknell 2001). 
One explanation is that cancer cells are more metabolically active than 
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normal cells, thus they accumulate more superoxide anion by electron transport 
chain in mitochondria as respiration byproducts. The resulting oxidative stress 
may cause further damage to both mitochondrial DNA and the respiratory 
chain, amplifying ROS generation (Zorov et al. 2006). In particular, generated 
ROS can be released into cytosol and trigger “ROS-induced ROS release” 
(RIRR) in neighbouring mitochondria. Tumor cells may also overproduce ROS 
for the upregulation of  an important ROS-producer enzyme such as NADPH-
oxidase (Meitzler et al. 2013). Another possible mechanism underlying the 
overproduction of ROS  that has been demonstrated in breast cancer is the 
overexpression of thymidine phosphorylase, an enzyme that catabolizes 
thymidine to thymine and 2-deoxy-D-ribose1-phosphate, that is able at last to 
generate ROS (Brown et al. 2000). Oxidative stress within breast carcinoma 
may also be caused by a breast specific mechanism, that implicates the 
oxidation of one-electron of 17b-estradiol to a reactive phenoxyl radical (Sipe 
et al. 1994). There are a number of reports, establishing a strong correlation 
between oxidative stress and estrogen presence (Han and Liehr 1994; Yager and 
Liehr 1996; Cavalieri et al. 2000) or estrogen receptor status (Musarrat et al. 
1996). In addition to metabolism of estrogen there is an ER mediated pathway 
capable of inducing ROS production through the regulation of antioxidant 
genes. It has been demonstrated that estrogen treatment causes a decrease in 
catalase activity followed by an increase in glutathione peroxidase activity, thus  
increasing the sensitivity to peroxide-induced cell damage in ER positive breast 
cancer cells, but not in ER negative breast cancer cells (Mobley and 
Brueggemeier 2004). 
The higher oxidative stress observed in cancer cells can also result from a 
decrease or inactivation of antioxidants (Oberley and Buettner 1979; Oberley et 
al. 2004; Ridnour et al. 2004; Senthil et al. 2004; Sinha et al. 2009). Tumor 
cells usually present very few antioxidative enzymes, such as catalase, SOD 
and glutathione peroxidase, making these cells very vulnerable to oxidative 
stress. A high percentage of tumors show low catalase activity, which means an 
advantageous adaptation for the tumor, that continues to benefit from the high 
levels of ROS. There are conflicting data in the results obtained by different 
researchers regarding the levels of antioxidant, especially SOD, in tumor tissue 
and in blood from cancer patients. In breast cancer, for example, several studies 
describe an increase of lipid peroxidation and a decrease of antioxidants 
(Khanzode et al. 2004; Sener et al. 2007).  The decrease of SOD activity could 
be related to the generation of free radicals that cause direct damage to the 
enzyme (Manoharan et al. 2004). However, other studies performed in 
neoplastic tissues have shown a greater presence of ROS and a high expression 
of SOD2 (Oberley and Buettner 1979; Cullen et al. 2003; Oberley et al. 2004; 
Ridnour et al. 2004), probably as a consequence of selective pressure towards 
stress adaptation. ROS can induce the up-regulation of SOD2 and other 
antioxidant enzyme through the modulation of the redox states of the 
transcription factors such as AP-1 and NFkB. The increase of ROS in tumor 
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cells may induce an increase of endogenous antioxidants in order to avoid 
intracellular lesions. Redox adaptation may be crucial also for drug resistance 
(Sullivan and Graham 2008). Redox adaptation, through the increase of 
endogenous antioxidants, may confer greater capacity to tolerate the action of 
exogenous stress, with capacity for increasing DNA repair and decreased 
apoptosis. As illustrated in figure 6, the high basal level of ROS in cancer cells 
make them more vulnerable to the increase of ROS that cause cell cycle arrest, 
apoptotic or necrotic cell death, depending on the degree of oxidative damage. 
In contrast, in normal cells, the ROS detoxifying capacity can protect cells from 
the increase of ROS levels  maintaining redox homeostasis (De Miguel and 
Cordero 2012). Since tumor and normal cells show different redox balance, one 
therapeutic strategy might be the induction of cytotoxic oxidative stress. 
 
 
 
 
Figure 6. Different balance of redox status in normal and cancer cells In normal cells, the 
redox detoxifying capability is capable to control exogenous oxidative stress from a ROS 
producer. In cancer cells, the load of endogenous ROS is already straining the buffering 
capacity of the cell, causing redox imbalance and cell death when an exogenous source of ROS 
is added. 
 
 This “oxidative therapy” could be achieved by two different methods: 
inducing the generation of cytotoxic levels of ROS, and inhibiting the 
antioxidant system of tumor cells (De Miguel and Cordero 2012). Since the 
antioxidant system is compromised in many tumors, one alternative approach 
could be to replace the antioxidant activity. In particular, the overexpression of 
SOD2 in human melanoma, fibrosarcoma, breast carcinoma, oral squamous 
carcinoma and prostatic carcinoma has determined a reduction of in vitro and 
in vivo tumor cell growth (Li et al. 1995; Oberley et al. 2004; Ridnour et al. 
2004). Overexpression of SOD2 leads to an accumulation of intracellular 
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peroxides that cannot be reduced, since catalase is downregulated in tumor 
cells. Indeed, it has been reported that the overexpression of either glutathione 
peroxidase or catalase reversed the growth inhibitory effects of SOD2 by 
altering the intracellular redox status (Li et al. 2000; Rodriguez et al. 2000). 
Ridnour and Oberley (2004) hypotized that the tumor suppressive effect for 
both the over- and under-expression of SOD2 may be explained by alterations 
in antioxidant balance characterized by the ratios of hydrogen peroxide 
generating to hydrogen peroxide-metabolizing enzyme activities. Their results 
reflect the dual nature of SOD2, acting as an antioxidant by removing 
superoxide, but also functioning as a pro-oxidant by producing hydrogen 
peroxide (Ridnour et al. 2004).  
Chemical agents, medical, diagnostic ionizing and non-ionizing radiations 
ROS are able to induce oxidative stress. The excessive production of ROS 
induce tumor cell death by  macromolecules damage and mitochondrial injury 
that causes the permeabilization of the mitochondrial membrane with release of 
cytochrome c, and activating caspase dependent apoptosis. In the same cases, 
the high levels of ROS that are generated may inhibit apoptosis at caspase 
level, and divert the process toward necrosis (Chandra et al. 2000; Conklin 
2004). The change from apoptosis to necrosis is critical in solid tumors, and 
requires considerable amounts of ROS, a decrease of ATP and alterations in 
mitochondrial electron-transport chain (Lee et al. 2000) (Lee Y.J. 1999). In 
tumor cells, also the induction of small amount of ROS could induce cell death  
by causing downstream signalling for the pro-apoptotic molecules. One 
example is p53, that detects oxidative damage in nuclear and mitochondrial 
DNA and regulates the expression of genes involved in redox status, cell-cycle 
regulation and apoptosis (Achanta and Huang 2004). 
 
 
Reciprocal regulation of AKT and ROS  
 
Akt pathway is involved in cell proliferation, differentiation, survival, 
and/or migration. Alterations of akt pathway lead uncontrolled cell signaling 
which promotes the acquisition of a cancerous phenotype. Although Akt gene 
mutations are rare in human cancer, several studies have shown Akt 
amplifications in human ovarian, pancreas, breast, and gastric malignant 
tumors (Staal 1987; Bellacosa et al. 1995; Cheng et al. 1996; Knobbe and 
Reifenberger 2003). Akt signaling exerts a direct influence on glycolysis in 
cancer cells by several mechanisms. Akt is able to regulate the localization of 
the glucose transporter GLUT1 to the plasma membrane (Clarke et al. 1994; 
Kim et al. 2007) and regulates hexokinase expression, activity, and 
mitochondrial interaction (Vander Heiden et al. 2001; Miyamoto et al. 2008). In 
addition, Akt may indirectly activate the glycolysis rate-controlling enzyme 
phosphofructokinase-1 (PFK1) by directly phosphorylating 
phosphofructokinase-2 (PFK2) (Deprez et al. 1997). Furthermore, the activity 
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of Akt correlated to the degree of glycolysis in many cancer cells (Elstrom et al. 
2004; Pelicano et al. 2006). Glucose metabolism plays an important role in 
hydroperoxide detoxification and the inhibition of glucose metabolism 
increases prooxidant production and cytotoxicity in cancer cells. If increased 
Akt pathway signaling is correlated with increased rates of glucose metabolism 
observed in cancer cells versus normal cells, then the inhibition of Akt pathway 
signaling would be expected to inhibit glycolysis and increase hydroperoxide 
production which would preferentially kill tumor cells versus normal cells via 
oxidative stress. Inhibiting glucose metabolism with Akt pathway inhibitors in 
cancer cells is hypothesized to limit the production of pyruvate and the 
regeneration of NADPH leading to increased steady-state levels of hydrogen 
peroxides from metabolic sources resulting in cytotoxicity. 
On the other hand, intracellular redox status plays a vital role in the 
reversible activation and inactivation of Akt pathway (Leslie et al. 2003; 
Yasukawa et al. 2005; Leslie 2006; Pelicano et al. 2006; Kaneki et al. 2007). 
For example, moderate levels of ROS activate Akt pathway signaling and 
promote cell survival, but high or chronic oxidative stress inhibits this pathway 
resulting in apoptosis. Activation of the Akt pathway occurs mainly through the 
oxidative inactivation of Cys-dependent phosphatases (CDPs) or the direct 
activating oxidation of pathway kinases (Leslie et al. 2003; Leslie 2006). For 
example, the phosphatase PTEN, the main phosphatase involved in the 
negative regulation of the Akt pathway, is inactivated by oxidation by both 
hydrogen peroxide and nitrosylation, posttranslational modifications which 
would hyper-activate the Akt signaling pathway. Akt can be also directly 
activated by oxidative stimuli such as hydrogen peroxide and peroxynitrite via 
posttranslational modification of Akt  (Leslie 2006; Clerkin et al. 2008; 
Nogueira et al. 2008). ROS-mediated posttranslational modification can also 
block akt function such as S-nitrosylation,  a covalent attachment of NO moiety 
to thiol sulfhydryls that reversibly block akt activation (Yasukawa et al. 2005; 
Leslie 2006; Kaneki et al. 2007). Many antitumoral compounds such as 
resveratrol, jacarone, 15d-PGJ2, curcumin, and quercetin downregulate 
phosphorilated and total levels of Akt via ROS generation (Woo et al. 2003; 
Granado-Serrano et al. 2006; Shin et al. 2009; Hussain et al. 2011; Massaoka et 
al. 2012; Okoh et al. 2013). Pre-treatment with scavenger of ROS or 
detoxifying enzymes prevented drug-induced inactivation of akt. However, the 
exact mechanism by which ROS release leads to inactivation of akt is not 
known. Shin S.W. and colleagues (2009) suggest that 15d-PGJ2 induced akt 
inactivation might represent a consequence of engagement of the ROS induced 
caspase cascade, even if they demonstrated that caspase inhibitors did not 
completely restore normal levels of akt. A possible mechanism that may 
contribute to akt inactivation by ROS generation is the activation of stress-
induced MAPKs, such as c-Jun N-terminal kinases (JNKs) but this cannot 
explain the downregulation of total protein form of akt (Shin et al. 2009). 
Another ROS mediated mechanism to block akt activity is the oxidation 
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of its chaperone HSP90. A recent study demonstrated that oxidative stress can 
inhibit HSP90 function by disruption the super-chaperone complex. Indeed, 
High ROS production can oxidize thiol groups of HSP90 protein, leading to 
protein aggregation and dysfunction. Consequently, akt and other client protein 
of HSP90 are degradated via proteasome (Sarkar et al. 2013). Alternatively, 
HSP90 can be cleaved by ROS at its amino-terminal aminoacid motiv 
determinig HSP90 and its client protein degradation (Beck et al. 2012). 
Since cancer cells are under increased metabolic oxidative stress 
compared to normal cells and the Akt pathway may be activated for survival 
under these oxidizing conditions, the therapeutical approach may take into 
account also inhibition of akt pathway and/or induction of ROS production, 
taking advantage of their multiple involvement in the control of cell 
proliferation.  
 
1.4 ROS AS SIDE EFFECT OF HIV-PIs 
 
Despite the clinical successes of HIV-PIs, accumulating clinical evidence 
suggests that treatment with PIs is implicated in the pathogenesis of metabolic 
syndrome (Carr et al. 1998; Ben-Romano et al. 2004; Chai et al. 2005). Most 
patients on PIs therapy develop a metabolic syndrome associated with partial 
lipodystrophy, hyperlipidemia, insulin resistance, premature atherosclerosis and 
myocardial infarction (Carr et al. 1998; Hui 2003; Koster et al. 2003). 
Supporting these evidences are human, animal, and cell-based studies, 
demonstrating that increased plasma cholesterol and triglyceride levels, and the 
development of lipodystrophy and insulin resistance, are the most common 
metabolic perturbations found with HIV-PIs treatment (Reyskens and Essop 
2014). 
 
 
Table 2. HIV-PIs and associated-complications 
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Cell and molecular mechanisms underlying PIs associated metabolic 
diseases seem to be related to overproduction of ROS (Mondal et al. 2004; 
Gills et al. 2007; Pyrko et al. 2007). Clinical studies suggested that PIs may 
induce oxidative stress in HIV positive patients (Jareno et al. 2002; Hulgan et 
al. 2003).  
Oxidative stress has been shown to induce insulin resistance, at least in 
culture cells (Bloch-Damti and Bashan 2005). The insulin signalling defect 
induced by exposure of adipocytes to hydrogen peroxide shares striking 
similarities to that observed with chronic exposure to nelfinavir, as both 
conditions induce a defect in signal propagation between PI3-kinase and Akt 
(Ben-Romano, Rudich et al. 2004). Although insulin-stimulated 
phosphorylation of insulin receptor substrate (IRS) proteins and their 
association with PI3kinase, as well as PI3kinase activity, are all maintained 
following nelfinavir treatment, the phosphorylation of downstream PI3K 
effector such as akt is impaired. The reduction in Akt phosphorylation may be 
due to a failure of insulin to promote its translocation to the plasma membrane, 
a process required for its phosphorylation and activation. Indeed, it has been 
observed that nelfinavir treatment or other oxidant agents impair capacity of 
signalling molecules to be normally relocated in response to insulin, and to be 
activated in a specific cell site (Ben-Romano et al. 2004). One important 
example is the block ROS-mediated of translocation of glucose transporter 
GLUT4 which leads to impaired glucose uptake (Rudich et al. 2001; Ben-
Romano et al. 2004; Bloch-Damti and Bashan 2005; Rudich et al. 2005). The 
increase of intracellular ROS may also directly inhibit insulin action by 
activating stress kinases involved in insulin signalling cascade such as MAPKs 
and NFkB and/or by inducing protein oxidative modifications (Evans et al. 
2003). One of the oxidative modification involved in insulin pathway is 
nitrosylation of insulin receptor, akt and IRS1 which determine an impaired 
insulin signaling to different levels (Carvalho-Filho et al. 2005; Yasukawa et al. 
2005). Oxidative modification can affect also several transcription factors such 
as NFkB and AP1 involved in the insulin pathway. These transcriptional 
factors, activated for direct oxidation or indirectly in response to oxidative 
stress (Ammendola et al. 1994), mediate GLUT1 transcriptional activation, 
thus increasing basal glucose uptake and mitochondrial ROS production. On 
the contrary, a massive ROS production reduces both mRNA and protein 
expression of GLUT4 by decreasing DNA-binding of nuclear protein to 
GLUT4 promoter (Pessler et al. 2001). 
Therefore, whereas short-term exposure to millimolar ROS concentrations 
results in the activation of insulin pathway by increased basal tyrosine 
phosphorylation and activation of glucose transport, high levels of ROS inhibit 
insulin-stimulated glucose uptake by activation of cellular stress kinases, 
impaired insulin-signaling cascade and changes in gene regulation and protein 
stability (Bloch-Damti and Bashan 2005). 
The exposure to nelfinavir not only induces peripheral insulin resistance 
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but also impairs glucose-stimulated insulin secretion from beta (Chandra et al. 
2009). Study conducted by Chandra et al (2009) revealed that nelfinavir is the 
most potent HIV-PI to suppress glucose stimulated insulin secretion and 
simultaneously increase oxidative stress to a significant level. Nelfinavir-
induced ROS production is associated with redox status perturbation with low 
protein levels but greater enzyme activity of antioxidant SOD1 and decrease in 
the intracellular levels of GSH. These conditions can represent both cause and 
effect of ROS production, since a reduction of ROS-detoxifying enzyme 
increases ROS production and, at the same time, oxidative stress can lead to 
inactivation or downregulation of these enzymes. The implication of oxidative 
stress in PIs-induced cell damages is demonstrated by co-treatment with 
antioxidants. In rat pancreatic insulinoma cells, nelfinavir dependent inhibition 
of glucose-stimulated insulin secretion is prevented by thymoquinone (Chandra 
et al. 2009), a potent antioxidant. Moreover,  in adipocytes, the SOD-mimetic 
antioxidant MnTBAP protects against nelfinavir-induced insulin resistance and 
apoptosis (Ben-Romano et al. 2006). Thus, nelfinavir alters glucose 
metabolism, and can impair glucose tolerance as well as whole-body glucose 
disposal, uptake, transport and phosphorylation, at the same time contributing 
to insulin resistance at peripheral sites. 
ROS production are well known triggers of ER stress (Hetz 2012), 
another molecular mechanism involved in HIV-PIs-induced side effects such as 
insulin resistance, dislipidemia, and  lypodistrophy. Indeed, the production of 
ROS interferes with protein disulphide bonding and results in misfolding of 
proteins that accumulate in endoplasmic reticulum lumen (Gotoh and Mori 
2006). One of the most important protein affected by ROS-induced ER stess  is 
sterol regulatory element binding protein SREBP, a lipid-status regulator that 
increase its intracellular levels after HIV-PIs treatment, causing cholesterol and 
sterol components production (Hirano et al. 2001; Riddle et al. 2001). Many 
studies reported that nelfinavir long-time treatment can affect adipose tissue by 
several mechanisms, including: induction of adipocyte necrosis (Vincent et al. 
2004); interference with terminal adipocyte differentiation (Zhang et al. 1999); 
interference with intracellular insulin signalling leading to the deregulation of 
glucose and lipid metabolism (Ben-Romano et al. 2004); accumulation of 
intracellular free cholesterol in hepatocytes (Zhou et al. 2006; Cao et al. 2010); 
activation of the expression of inflammatory cytokines in macrophage (Zhou et 
al. 2007). The subsequent increase of free fatty acids levels can affect 
endothelial function and survival, and contribute to cardiovascular morbidity in 
PIs therapy treated patients. 
It has been reported that HIV-PIs treatment determines an increase of the 
incidence of cardiovascular diseases probably through ROS production. 
Increased production of ROS is associated with coronary atherosclerosis, 
ischemia, reperfusion injury, and progression of chronic congestive heart 
failure (Moskowitz and Kukin 1999). In particular, oxidative stress is one of 
the important mechanisms of vascular injury and endothelial dysfunction, both 
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recognized as critical initiating factors in atherogenesis and other 
cardiovascular diseases. Indeed, it has been proposed that an increased 
extracellular or intracellular production of ROS induces vascular smooth 
muscle cells apoptosis in atherosclerotic plaque (Irani 2000). Using this cell 
model, it has been demonstrated that nelfinavir induces an increase of ROS 
production leading to apoptotic cell death (Rudich et al. 2005). 
PIs increase ROS production also in human aortic endothelial cells, and 
increase the endothelial properties of leukocyte recruitment leading to vascular 
dysfunction (Mondal et al. 2004).  
It has been demonstrated that ritonavir significantly impairs vasomotor 
activities through the increase of oxidative stress and the decrease of 
endothelial nitric oxide synthase (eNOS) in porcine coronary artery and 
endothelial cells. A decrease of eNOS expression leads to a decrease of NO 
production, which may contribute to the pathophysiology of several major 
disease of the cardiovascular system. In addition, decreased eNOS expression is 
always accompanied by the overproduction of ROS, a known risk factor for 
cardiovascular disease (Fu et al. 2005). In the model of porcine coronary artery 
cultures, ritonavir, amprenavir and saquinavir have more detrimental effects 
than indinavir and nelfinavir, resulting in vasomotor dysfunction, eNOS 
downregulation, and superoxide anion overproduction. In particular, ritonavir 
induces smooth muscle cell and endothelial cell injury while indinavir and 
nelfinavir have very limited effects on vasomotor function in this model 
(Zhong et al. 2002; Chai et al. 2005). The source of PIs-induced ROS  is not 
clear but fluorescence microscopy analysis of ROS and cellular mitochondria 
co-localizion in endothelial cells have suggested that mitochondrial ROS are 
involved  (Jiang et al. 2007a). In these cells, the increase of ROS determines a 
decrease in the mitochondrial transmembrane potential and mitochondrial 
dysfunction, thus promoting endothelial dysfunction but not endothelial cell 
death. PIs-induced ROS production results in lipid peroxidation, that is 
abrogated by overexpression of mitochondria-targeted catalase (Jiang et al. 
2007a). Moreover, high ROS intracellular levels determine calcium overload by 
oxidation of sulfhydryl groups of several receptor, ionic channels and pumps, 
leading to mitochondrial damage, ATP-generating capacity impairment, and 
dysfunction of electrical signaling in the myocardium (Reyskens and Essop 
2014). 
Although the specific cell mechanism of ROS production has not been 
elucidated, PIs-induced ROS may prove to be an important common cell 
mechanism in HIV-PIs-induced side effects. The identification of novel 
nelfinavir-derived molecules with anti-proliferative activity might determine 
lower side effects and improve the therapeutic range. 
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1.5 NELFINAVIR CHEMICAL DERIVATIZATION 
 
The use of nelfinavir in HAART protocols for AIDS therapy as well as its 
strong anti-tumoral potentiality is undermined by its many side effects. To 
improve therapeutic efficacy in AIDS therapy, limit side effects and/or generate 
effective drugs against new HIV-mutants, several pharmaceutical companies 
have developed, an increasing number of second-generation protease inhibitors, 
either with or without a flexible structure (Rusconi and La Seta Catamancio 
2002). Nelfinavir has attracted the attention of synthetic chemists due to its 
huge market, unique structural features comprising five stereogenic centers and 
a core four carbon backbone in which each carbon is attached to a heteroatom.  
 To data no Nelfinavir-analogues is side effects-free, or more effective 
than nelfinavir or other FDA-approved HIV-PIs.  A  strategy for the synthesis of 
thiophene containing nelfinavir analogues has been developed by Bonini et al. 
(2004), with the preparation of key-chiral compounds, which can be utilized for 
the synthesis of different potential HIV-PIs. Data deriving from biological 
experimental strategies and theoretical data revealed a low activity of derivative 
compounds compared to the Nelfinavir unmodiﬁed molecule (Bonini et al. 
2004, Bonini et al. 2005). Zhou and Yang (2008) designed a series of hybrid 
molecules as non-peptidic HIV-PIs by incorporating methyl sulfonamide 
moiety of amprenavir into hydroxyethyl decahydroisoquinoline backbone of 
nelfinavir. Although derivatives exhibit moderate to significant HIV-protease-
inhibitory activities, to date the best revealed inhibitory activity is essentially 
equipotent to classical HIV-PIs (Zhou et al. 2008). 
While chemical design based on HIV-protease/substrate interaction is 
important to synthesize novel protease inhibitors capable to improve clinical 
trend in HIV-infected subjects (Bonini et al. 2010), the absence of defined 
molecular target at the basis of anti-cancer activity of nelfinavir, makes the 
development of novel anti-cancer compounds very difficult. However, the 
characterization of the functional groups of nelfinavir responsible for its 
biological activities are relevant to support the design of novel, more effective 
anti-tumoral compounds compared to actual chemotherapeutic agents. 
2. AIMS OF THE STUDY 
 
The advent of HIV-PIs has led to a reduced incidence and/or regression of 
AIDS-associated tumors by a non-immune mediated mechanism. Indeed, the 
anti-cancer effect cannot be explained by the ability of these drugs to suppress 
HIV replication and thereby reconstitute the immune system (Monini et al. 
2004). Based on these evidences, many researchers attempted to evaluate the 
anti-cancer activity of the most used HIV-PIs including amprenavir, indinavir, 
lopinavir, nelfinavir, ritonavir, and saquinavir in HIV-free models. Nelfinavir 
represents the most potent anti-tumor HIV-PIs. Although the molecular 
mechanisms at the basis of its anticancer activity has not been elucidated yet, 
many studies suggested that inhibition of akt pathway is a relevant mechanism 
by which nelfinavir exerts anti-tumor effect in different cancer types. 
Controversial and few informations have been generated by studies on 
nelfinavir activity in breast cancer, that established its anti-proliferative effect 
in this tumor. However, the development of many side-effects in HIV-patients 
treated with nelfinavir has reduced the interest versus nelfinavir as anti-tumoral 
drug. Recent evidences demonstrated that the alteration of redox state is  
responsible for the side effects observed in HIV-positive patients treated with 
this drug, but the involvement of ROS in the molecular mechanism underlying 
its anti-cancer effects has not been investigated .   
Aim of the present thesis is to study the mechanisms at the basis of 
anticancer activity of nelfinavir in breast cancer, and to identify novel 
nelfinavir-derivatives with increased efficacy and reduced cell toxicity. 
 
To this purpose, I analyzed: 
a) the anti-proliferative effects and specificity of nelfinavir in breast cancer 
cell lines 
b) the effect of nelfinavir on akt pathway  
c) the role of  redox status in nelfinavir anti-cancer activity. 
d) the chemical nelfinavir structure in order to design and synthesize novel 
anti-tumor compounds. 
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3. MATERIAL AND METHODS 
 
3.1 Cell Culture 
 
 Human breast cancer (MCF-7; MDA-MB231), human thyroid tumor 
(TPC), human lung adenocarcinoma (Calu), human hepatoma ( HepG2), and 
colon adenocarcinoma (HT-29) were grown at 37 °C in Dulbecco’s modified 
Eagle’s medium (DMEM) (Life Technologies) containing 10 mM glucose 
supplemented with 10% fetal calf serum (GIBCO) and 100 units/mL each of 
penicillin and streptomycin and 2 mmol/L glutamine  and incubated in standard 
culture conditions (95% air and 5% CO2 at 37 °C).  
 
3.2 Culture of human primary mammary epithelial cells 
 
Human mammary epithelial cells (HMEC) were derived from surgical 
specimens from normal women who had undergone reduction mammoplasty, 
after informed censent.  Epithelial cells were culled and grown by the method 
of Stampfer (Labarge et al. 2013). Briefly, upon receipt, tissue was washed 
extensively in phosphate-buffered saline (PBS) supplemented with 200 U of 
penicillin, 200 g/ ml streptomycin and 5 µg/ml fungizone (all from SIGMA), 
then minced finely and disaggregated for 18-20 min in 0.1% collagenase type 
III (Life Technologies). Digested tissue was removed from the incubator, the fat 
supernatant tissue was removed  and the tube was shaken vigorously by hand to 
disaggregate any remaining large clumps. Three cell populations (epithelial 
breast cells, stromal breast cells and organoid substance) were then isolated 
using differential centrifugation. For the first 24 h, cells from the organoid and 
epithelial fractions were plated in 75% organoid medium (OM) to promote cell 
attachment. OM consisted of DMEM/F12 supplemented with 100 U/ml 
penicillin, 100 g/ml streptomycin, 2 mM glutamine, 10 mM Hepes, 0.075% 
bovine serum albumin (BSA), 10ng/ml cholera toxin, 0.5g/ml hydrocortisone, 
5g/ml insulin and 5ng/ml epidermal growth factor (EGF) (all from SIGMA).  
After 24 h media was removed and replaced with OM. Cells were maintained 
in this way for the duration of the culture. To remove the fibroblasts from 
HMEC, it was performed Differential Trypsinization (DT), based on the rapid 
detachment of fibroblasts from the surface plastic (Olumi et al. 1999). The 
predominance of epithelial cells and the absence of fibroblasts was confirmed 
by immunofluorescence staining with the broad spectrum, cytokeratin antibody 
AE1/AE3 and the lack of staining for vimentin (Santa Cruz). 
 
3.3 Reagents and inhibitors 
 
 Nelfinavir mesylate hydrate was dissolved in DMSO to a final 
concentration of 50 mM and stored at -20°C. It was obtained through the NIH 
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AIDS Research and  Reference Reagent Program, Division af AIDS, NIAID, 
NIH. It was used at indicated concentration and added in colture medium each 
48 hours. Nelfinavir-derivatives were designed and producted by University of 
Salerno, Department of Pharmacy. Intracellular translation inhibitor 
cycloheximide (Sigma), proteasome inhibitor MG-132 (Sigma), HSP-90 
inhibitor 17-AAG (Calbiochem), PI3K inhibitor LY294002 (Sigma), ROS 
scavenger tocopherol (Sigma) were used at indicated concentrations. 
 
3.4 Cell Viability Assay 
 
 Cells were seeded into 96-well plates to a density of 5x 10
4
 cells/well. 
After 24 hours of growth to allow attachment to the wells, nelfinavir or 
nelfinavir-derivatives were added at different concentrations for indicated time 
points. At the end of incubation times, PrestoBlue™ Reagent (Invitrogen) were 
added directly to cells in culture medium for 2 hours at 37
o
C in the dark. 
PrestoBlue® reagent is a resazurin-based solution that functions as  a cell 
viability indicator and it is modified by the reducing environment of the viable 
cell. This change was detected using absorbance measurements at 570 nm and 
the values normalized to the 600 nm values for the experimental wells. Results 
were expressed as percentage relative to vehicle-treated control (0.5% DMSO 
was added to untreated cells). 
 
3.5 Growth Curve 
 
Cells were seeded in 12-well culture plates at density of 1x104 cells/well 
and allowed to attach for 24h. Cells were then treated with indicated reagents. 
Attached cells were harvested and a cell count performed using a Bürker 
chamber, until 6th day. 
 
3.6 Cell cycle analysis 
 
For FACS analysis cells were seeded in 6-well plates at density of 3x105 
cells/dish and treated as indicated. Attached MDA-MB231 and MCF-7 cells 
were collected and fixed over-night in ice-cold 70% ethanol at -20°C. Washed 
pellets were resuspended in PBS containing 250μg/ml RNAseA (Roche)  and 
10μg/ml Propidium Iodide (PI) (Sigma), incubated for 30’ at room temperature, 
and analyzed for emission in PE-Texas Red channel. The samples were 
acquired with a CYAN flow cytometer (DAKO Corporation, San Jose, CA, 
USA). To remove artifacts such as doublets and aggregates from the analysis, 
an electronic doublet discrimination was performed using the area and width of 
the fluorescence PE-texas red pulse. 
The cell cycle distribution, expressed as percentage of cells in the G0/G1, 
S, and G2/M phases, was calculated using SUMMIT software. 
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3.7 Annexin V/PI staining 
 
 MDA-MB231 and MCF-7 cells were plated at 1x10
5
 in 6-well plates and 
washed with PBS1X and then with Annexin V Binding Buffer. After 
centrifugation at 2000 rpm for 3 min, the cells were resuspended in 100µl of 
Annexin V Binding Buffer (Biolegend) and incubated with 5 μl of FITC-
conjugated  Annexin V (Biolegend) for 15 min at 25°C in the dark. Finally, 400 
μl of Annexin V Binding Buffer  and 2 μl of 500 μg/ml PI was added to each 
sample just before analysis.  PI can penetrate only in non-vital cells, whereas 
Annexin V binds to living cells with exposed phospholipid phosphatidylserine, 
an early marker of apoptosis. PI single positivity represents necrosis, single 
Annexin V staining early apoptosis, double positivity (annexin V and PI) 
indicates late apoptosis. Samples were acquired with a CYAN flow cytometer 
(DAKO Corporation, San Jose, CA, USA) and analysed using SUMMIT 
software. 
 
3.8 Measurement of ROS intracellular levels 
 
Basically, cells are incubated with the fluorescent, lipophilic 
dihydrodichlorofluorescein diacetate (H2DCF-DA)(Calbiochem) which can 
diffuse through the cell membrane. Inside, the acetate groups are cleaved by 
cellular esterases so the resulting H2-DCF cannot leave the cells. Reaction with 
intracellular ROS, primarily hydrogen peroxide (H2O2), results in the 
fluorescent molecule DCF (max. emission ~ 530 nm). Breast cancer and 
primary normal cells were seeded in 6-well plates at density of 3x10
5
 cells/dish 
and treated with 10µM nelfinavir at different indicated time point. Cells were 
rinsed with PBS and incubated with 5uM H2DCF-DA in the serum-free fresh 
medium. After 30 min incubation at 37 
0
C in the dark, the cells were washed, 
harvested  and green fluorescence intensity in the cells was examined by FACS 
(DAKO Corporation, San Jose, CA, USA) analysis using SUMMIT software. 
 
3.9 Lipid peroxidation analysis 
 
Lipid peroxidation was analysed using the parameters indicated in the 
Lipid Peroxidation (MDA) assay kit instructions (Abcam). Briefly, cells were 
seeded at density of 1x10
6
cells, treated with nelfinavir at indicated time,  
lysated on ice in MDA lysis buffer and centrifuged (13000xg, 10 min) to 
remove insoluble material. The supernatants were placed into new vials with 
Thiobarbituric Acid (TBA) solution for 60 min at 95
o
C  and cooled in ice bath 
for 10 min. The MDA-TBA adducts were quantified colorimetrically at 532nm 
using a microplate reader. 
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3.10 SOD activity assay 
 
SOD Activity Assay kit (Abcam) was used to determine the SOD activity 
in breast cancer cell lines treated for 30 min, 3h, 24h and 48h with 10µM 
nelfinavir. The analysis of enzymatic activity was based on detection of WST-1 
products (water-soluble formazan dye) upon reduction with superoxide anion. 
Briefly, cells were homogenized in ice cold 0.1M Tris/HCl, ph 7.4 containing 
0.5 %Triton X-100, 5mM β-ME, 0.1mg/ml PMSF. After centrifugation 
(14000xg 5min at 4°C), supernatants were incubated with WST Working 
Solution and Enzyme working solution for 20 min at 37 C. SOD activity (%) 
was calculated as indicated in the assay kit instructions using  absorbance 
values at 450nm. 
 
3.11 Glutathione reductase assay 
 
Abcam’s Glutathione Reductase Assay kit is a highly sensitive 
colorimetric assay and was used for measuring GR activity in biological 
samples. Briefly, MCF-7 and MDA-MB231 cells (1x10
6
 cells) were lysated on 
ice in assay buffer, then centrifuged at 10000xg for 15 min at 4
o
C and 
supernatants were collected for assay. In the assay, GR reduces glutathione, 
which reacts with 5,5’-Dithiobis (2-nitrobenzoic acid) (DTNB) to generate 
yellow TNB
2-
. The absorbance values were measured at 405 nm by microplate 
reader. 
 
3.12 Quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) 
 
 Total RNA were extracted from MDA-MB231 cells using trizol reagent 
(Invitrogen), purificated with Qiagen RNeasy mini-kit and reverse transcribed 
using a High Capacity Reverse Transcriptase Kit (Applied Biosystems). QRT-
PCR was performed using a BioRad IC5 thermo cycler (Bio-Rad laboratories, 
Hercules, CA) using specific primers (Nakatani et al. 1999): 
h-Akt1      5′-ATGAGCGACGTGGCTATTGTGAAG-3′ forward 
                  5′-GAGGCCGTCAGCCACAGTCTGGATG-3′reverse,  
h-Akt2    5′-ATGAATGAGGTGTCTGTCATCAAAGAAGGC-3′ forward 
                 5′-TGCTTGAGGCTGTTGGCGACC-3′reverse,  
h-Akt3     5′-ATGAGCGATGTTACCATTGT-3′ forward 
                 5′-CAGTCTGTCTGCTACAGCCTGGATA-3′reverse. 
Cycle threshold (Ct) values from 3 indipendent experiments were 
normalized to the internal β-actin control. The ratio of fold change was 
calculated using the Pfaffl method (Pfaffl 2001). 
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3.13 Western Blot and immunoprecipitation procedures 
 
Cells were washed in PBS buffer and lysed on ice for 30 min in RIPA 
buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 1% NP-40, 2mM EDTA, 2mM 
PMSF, 5µg/mL leupeptin, 5µg/mL pepstatin). Lysates were quantified by 
Biorad DC protein assay. An equal amount of proteins from each sample was 
loaded with lamely buffer. Protein were resolved by SDS-PAGE and transferred 
to an Immobilion P membrane (Millipore Corporation, Bedford, MA). 
Membranes were blocked by incubation with PBS 0,2% tween, 5% nonfat dry 
milk for one hour at room temperature. the membranes were then incubated 
overnight with primary antibodies at 4
o
C, washed for 40 min with PBS 0,2% 
tween and incubated for one hour with a horseradish peroxidase-conjugated 
secondary antibodies. finally, protein bands were detected by an enhanced 
chemiluminescence system (ECL, Amerscham). Computer-acquired images 
were quantified using ImageQuant software (Amerscham). 
For Immunoprecipitation assay, the cells were lysed in RIPA buffer and 
500µg of total lysate were incubated with primary antibodies vs protein of 
interest for one hour and with Protein G plus/protein A agarose beads 
(Calbiochem) for other two hours. Non immune rabbit or mouse IgG were used 
as control. Mouse monoclonal antibodies to HSP90, cyclin B, p21, cytochrome 
c, Bcl-2, β-actin,  rabbit polyclonal to MDM2, cyclin A, cyclin D, cyclin E, 
SOD1, SOD2, Bak and caspase 9 and goat anti-akt were all purchased by Santa 
Cruz Biotechnology, CA, USA. Rabbit polyclonal to phospho-akt (Ser 473), 
pospho-PRAS40 (Thr 246) and phospho-Rb (Ser 807/811) were purchased 
from Cell Signaling, Boston, MA, USA. 
 
3.14 Statistical analysis 
 
Student’s t-test was used to assess statistical significance and a p-
value<0.05 was deemed significant. Statistics were computed with GraphPad 
Prism software (San Diego, CA). 
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RESULTS 
 
4.1 Effect of nelfinavir on viability and proliferation of cancer cells. 
  
   To evaluate the anticancer activity of nelfinavir, I performed a cell 
viability assay and cell-growth analysis in different cancer models: TPC 
(thyroid), HT-29 (colon), HEPG2 (liver), CALU (lung). As depicted in figure 7, 
nelfinavir significantly inhibited the growth of all these tumor cells. In 
particular, 10µM nelfinavir was able to reduce cell population to 40% in 
HEPG2 cells and HT29 following 24 of treatment, whereas CALU and TPC 
cells resulted more resistant  to drug cytotoxic effects and required the highest 
concentration of  nelfinavir (20µM) to significantly reduced cell viability. 
 
 
 
 
Figure 7. Cytotoxic effect of nelfinavir on cancer cells 
A) TPC, CALU, HEPG2, HT-29 were treated with 5µM,10µM, 20µM nelfinavir, and cell 
viability was measured by MTT assay after 24 and 48 hours (h) of treatment. The histograms 
represent cell viability percentage relative to untreated cells (control). B) Growth curves of  the 
same cancer cells untreated or treated with 10µM nelfinavir for 24, 48, 72 and 144 hours. Each 
value is the mean ± S.D. of three indipendent experiments. Significant (* p-value< 0.05) 
differences in cell viability were observed in cell treated with drug compared to control cells 
(ctrl).  
 
To determine the effectiveness of anti-proliferative activity of nelfinavir in 
human breast cancer, I performed a cell viability assay in two different cell 
lines, MDA-MB231 and MCF-7 cells. These cells are widely used for testing 
drugs in vitro since they represent two different cell models of breast 
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carcinomas. These tumor cell lines were treated for 24 hours and 48 hours with 
5µM,10µM and 20µM of Nelfinavir, that represent a therapeutic range in 
HAART protocols. As shown in figure 8, nelfinavir significantly decreased cell 
viability in a dose-dependent manner in both cell lines although MCF-7 
resulted more sensitive to nelfinavir treatment. Breast epithelial cells were 
drawn from mammary gland of healthy subjects undergoing aesthetic reductive 
surgery, and used to determine whether nelfinavir reduced viability of normal 
cells. Data suggest that nelfinavir affected the viability of breast normal cells 
only at high concentration (20µM). The analysis of the growth of MDA, MCF-
7 and breast primary normal cells confirmed the selectivity of the anti-
proliferative action of nelfinavir (10µM) on tumor cells. For this reason all the 
following experiments were performed with 10µM nelfinavir. 
 
 
 
 
Figure 8. Nelfinavir exhibits anti-proliferative effects in breast cancer cell lines 
 A) MTT assay to assess cell viability in MDA-MB231, MCF-7 and normal breast epithelial 
cells, treated with indicated concentration of nelfinavir for 24 and 48 hours. B) Growth curves 
for 10µM nelfinavir at indicated times in MDA-MB231, MCF-7 and breast epithelial cells. The 
data show the mean ± S.D. of three indipendent experiments. Significant (* p-value< 0.05) 
differences in cell viability were observed in cell treated with the drug compared to control 
cells (ctrl). 
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4.2 Cell-cycle profile and cell-death analysis in nelfinavir-treated 
cells.  
 
The inhibition of cell-growth/viability in tumor cells treated with 
nelfinavir can sustain different biological mechanisms such as cell cycle block, 
apoptosis, necrosis and senescence. Firstly, I evaluated cell cycle in MDA-
MB231 and MCF-7 cells. FACS analysis revealed that nelfinavir induced a 
slight increase of G1 phase population percentage and decrease of S and G2 
phase cell percentage following 24 hours of treatment of MDA-MB231 cells. 
Otherwise, nelfinavir did not affect MCF-7 cell-cycle (figure 9). 
 
 
Figure 9. Cell-cycle analysis in nelfinavir treated breast cancer cell lines 
 MDA-MB231 and MCF-7 cells were treated with 10µM nelfinavir for 6-72 hours (h). 
Thereafter, the cells were washed, fixed and stained with propidium iodide, and analyzed for 
DNA content by flow cytometry as described in Material and Methods. These data represent the 
mean ± S.D. of four indipendent experiments. * p-value< 0.05, versus control cells (ctrl). 
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To better investigate the induction drug-mediated of cell-cycle arrest, I 
performed a Western Blot analysis of different proteins involved in cell-cycle 
progression control such as Rb, p21, cyclins A, B, D, E. As shown in figure 10, 
nelfinavir reduced the levels of phosphorylated Rb, cyclin A, cyclin B, cyclin 
D, increased the expression levels of p21 in breast cancer cell lines but not in 
normal cells. Moreover, the expression of cyclin E was modified only in MDA-
MB231. Although both cell lines showed a similar protein expression profile, 
biological effects of nelfinavir treatment resulted different in MDA-MB231 and 
MCF-7 cells. Indeed, whereas in the former I observed a Go/G1 block, MCF-7 
cell-cycle was not affected by nelfinavir.  
 
 
 
Figure 10. Specific anti-proliferative activity of nelfinavir in breast cancer cells compared 
to normal cells A) MDA-MB23, MCF-7 and primary breast epithelial cells were treated with 
10µM nelfinavir for 24 hours and protein lysates immunoblotted for different cell-cycle 
regulators: pRB, cyclin A, B, D, E, p21 and β-actin, used as loading control. B) Densitometric 
analysis of proteins signals relative to actin signal. The values represent the means ± S.D. of 
three indipendent experiments and compared to control value (* p-value < 0.05) 
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Cell-cycle analysis also revealed that nelfinavir increased the fraction of 
tumor cells with sub-G1 DNA content. Therefore, I investigated whether this 
result, as well as the reduction of cell growth/viability, was correlated to cell 
death mechanisms. To this aim, breast cancer cells were treated with 10µM 
nelfinavir for different time points and stained with Annexin V conjugated with 
FITC, which marks apoptotic cells, and propidium iodide as a general cell 
death marker. Nelfinavir treatment resulted in time-dependent increase in 
proportions of apoptotic and necrotic cells (figure 11). In particular, nelfinavir 
rapidly induced necrosis followed by apoptotic process in both cell lines. A 
comparison between these cell lines death profile pointed out different cell 
death timetables. Indeed 12 hours of nelfinavir treatment increased to 20% the 
cell-death percentage achieving about 50% of necrotic and apoptotic cells after 
48 hours of treatment in MCF-7 cells. In MDA-MB231 cells, no change in the 
cell-death pathways accured before 48 hours of nelfinavir treatment, and more 
than 72 hours of drug treatment  were required to determine a massive increase 
of propidium iodide-positive and annexin V-positive cells.  
 
    
 
 
Figure 11. Nelfinavir induces necrosis and apoptosis in breast cancer cell lines 
MDA-MB231 and MCF-7 cells were treated with 10µM nelfinavir for indicated time points 
and cells were subsequently stained with FITC-conjugated annexin V and propidium iodide and 
analyzed by flow cytometry. 
 
48 
 
To confirm the induction of cell death by nelfinavir, I tested the effects of 
this drug on the proteins involved in cell death pathway by western blot 
analysis. As shown in figure 12, nelfinavir-treated cells increased the 
expression levels of pro-apoptotic mitochondrial factor Bak, induced a  
citochrome c release from mitochondria, and subsequently the activation of 
caspase 9 in time-dependent manner. Therefore, parallel to the cytotoxic effect 
revealed by MTT and FACS analysis, treatment of MDA-MB231 and MCF-7 
cells with nelfinavir, for 72 and 24 hours respectively, increased the levels of 
apoptotic markers. So, the short-term nelfinavir-treatment induced directly cell-
death in MCF-7cells and did not have a prominent cytotoxic effect in MDA-
MB231, which resulted blocked in G0/G1 phase. However, prolonged cell-
cycle block induced necrosis and activation of the apoptotic process. These data 
suggest a greater resistance of MDA-MB231 cells to nelfinavir-induced 
cytotoxicity. 
 
 
 
      
Figure 12. Time-course of apoptosis regulators affected by nelfinavir 
A) Western blot analysis was performed in MDA-MB231 and MCF-7 treated with 10µM 
nelfinavir at indicated time points and bak, cytochrome c and pro-caspase 9 proteins were 
revealed using specific antibodies. β-actin immunoblotting was used as loading control. B) 
Densitometric analysis of proteins signals relative to actin signal. The present data represent the 
means ± S.D. of three indipendent experiments and compared to control value (* p-value< 
0.05) 
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4.3 Breast cancer cells treated with nelfinavir downregulate akt 
pathway 
 
Akt signaling pathway has been implicated in the regulation of cell cycle 
progression and cell proliferation. Activation of akt is also associated with 
protection of cells from apoptosis (Datta et al. 1997; Burgering and Medema 
2003; LoPiccolo et al. 2008). To analyze whether inhibition of akt is related to 
nelfinavir-induced cell cycle arrest and/or apoptosis, I evaluated akt expression 
and phosphorylation by western blot. MDA-MB231 and MCF-7 cells were 
treated with nelfinavir for different times, depending from cell-death profile: 3, 
6, 24, 48, 72 hours for MDA-MB231 cells and 30 minutes, 3, 6 and 24 hours 
for MCF-7 cells. As shown in figure 13, the treatment with nelfinavir for 6 
hours determined a significant reduction of akt phosphorylation in both cell 
lines. An interesting data is that also total akt protein was downregulated 
following 24 hours of drug treatment: this suggests that enhanced akt de-
phosphorylation at this time point could be explained by reduction in total akt 
protein levels. 
To determine whether the downregulation of akt affects downstream 
targets and is specific for tumor cell lines, I analyzed the expression  levels of 
the most representative proteins involved in akt signaling in breast cancer cells 
and  normal breast epithelial cells. Western blot analysis revealed a reduction of 
all akt analyzed targets such as phospho-PRAS, MDM2 and Bcl2, in MDA-
MB231 and MCF-7 cells, while no effects were observed in normal cells 
(figure 13C). 
 
 
 
Figure 13. Nelfinavir inhibits akt signaling in cancer but not in normal breast cells 
Protein lysates from MDA-MB231 cells (A) or MCF-7 cells (B), subjected to 10µM nelfinavir 
treatment for the indicated time points, were immunoblotted for phosphorylated and total akt.  
C) MDA-MB231, MCF-7 and normal breast epithelial cells were treated with 10µM nelfinavir 
and lysed after 24 hours. Protein lysates were subjected to western blot analysis of akt and its 
effectors phospho-PRAS, MDM2 and Bcl-2, using specific antibodies. β-actin immunoblotting 
was used as loading control.  
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4.4 Nelfinavir induces akt downregulation by disruption of akt-
HSP90 complex  
 
In order to understand whether akt decrease occurred at transcriptional 
level, I analyzed the expression of akt mRNA in MDA-MB231 cells by a 
reverse transcription-PCR experiment. As shown in figure 14A, the treatment 
with nelfinavir for 24 hours did not inhibit the expression of all three akt 
isoforms (Akt1, 2, 3) mRNA. To investigate whether nelfinavir-mediated akt 
regulation was at post-transcriptional level, I analyzed akt stability, treating 
MDA-MB231 cells with cycloheximide to block new protein synthesis. 
Figure 14B showed that nelfinavir modified akt turnover reducing of 20% 
akt expression levels in presence of cycloheximide compared to values derived 
from single cycloheximide treatment. The result suggested that nelfinavir  does 
not affect de novo protein synthesis. 
Because akt stability is mainly dependent from its association with 
chaperone HSP90, I evaluated the association between akt and HSP90 by co-
immunoprecipitation assay. As shown in figure 14C, nelfinavir reduced 
akt/HSP90 association after 6 hours of treatment without affecting akt and 
HSP90 expression levels. Nelfinavir-mediated disruption of HSP90/akt 
complex could explain the significant and fast de-phosphorylation of akt and 
downregulation of total akt. To determine whether nelfinavir induces akt 
degradation and whether proteasome mediates this process, cells were treated 
with MG132, a proteasome inhibitor, and akt was detected by western blot 
analysis (figure 14D). Proteasome inhibitor impaired  nelfinavir effects 
restoring akt protein levels, thus suggesting that nelfinavir induced akt 
degradation via proteasome 
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Figure 14. Nelfinavir causes a dissociation of akt/HSP90 complex and akt degradation via 
proteasome A) MDA-MB231 cells were treated with 10µM nelfinavir for 24 hours and mRNA 
expression levels of three akt isoforms were analyzed by RT-PCR as indicated in Material and 
Methods. The values represent mean ± SD of three indipendent experiments normalized  to 
untreated cell values. B) MDA-MB231 cells were treated with 10µM nelfinavir for 24 h and 
incubated with 0,5µg/mL cycloheximide for the last 1 hour or 6 hours of treatment. Protein 
lysates were subjected to western blot analysis for akt and β-actin.  C) Cells were treated with 
nelfinavir for 6 h, then lysed, immunoprecipitated (IP) using akt antibody and immunoblotted 
for HSP90 or akt. D) Lysates from MDA-MB231 cells co-treated with nelfinavir for 24 hours 
and proteasomal inhibitor MG132 (10µM) for the last 8 hours of drug treatment were subjected 
to western blot for akt and β-actin. Akt signal following the indicated treatments were 
quantified by densitometry and normalized on β-actin values. The values are representative of 
three indipendent experiments. Error bars represent S.D. and *p-value < 0.05. 
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4.5 Sinergistic effect of nelfinavir with PI3K or HSP90 inhibitors 
 
To confirm the involment of akt pathway and HSP90 activity in 
nelfinavir-mediated anti-cancer effects, I determined whether canonical 
inhibitors of akt pathway or HSP90 activity were able to reduce tumor cell-
growth. Cells were treated with 17-AAG, inhibitor of HSP90 chaperone activity 
and LY 294002, PI3k inhibitor. First I analyzed the expression levels of 
phosphorylated and total akt in MDA-MB231 cells treated with different 
concentrations of these inhibitors. As shown in figure 15, both 17-AAG and 
LY294002 determined a reduction of akt phosphorylation. In addition, 1µM 17-
AAG caused a downregulation of total akt, thus confirming the important role 
of HSP90 in akt stability. To determine whether these compounds as well as 
nelfinavir affect cell growth, I performed cell counts at  24, 48 and 72 hours of 
treatments. Both 17-AAG and LY294002 determined a reduction of cell 
number in a time dependent manner, even if nelfinavir showed more efficacy 
than the other two compounds (figure 15C).  
 
 
 
 
Figure 15. 17-AAG and LY294002 enhance nelfinavir anti-proliferative efficacy 
Dose-response curve of 17-AAG (A) at 12 hours and of LY204002 (B) at 24 hours in MDA-
MB231. Total cell lysate was used to perform western blot analysis of phopho-akt, akt, HSP90 
and β-actin by specific antibodies. β-actin immunoblotting was used as a loading control. C) 
MDA-MB231 cells were treated with  500nM 17-AAG, 10µM LY294002 or 10µM nelfinavir 
for the indicated time points to assess cell-growth curve. D) MDA-MB231 cells were incubated 
with 500nM 17-AAG or 10µM LY294002 in presence of different nelfinavir concentration and 
cell number analyzed at 48 hours of treatments. Values represent the means ± S.D. of three 
indipendent experiments. 
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According to the literature (Gupta et al. 2007), these data suggest that 
nelfinavir has a broad spectrum of activity, not only restricted to akt 
downregulation. Moreover, the combination of nelfinavir with 17AAG and 
LY294002 improved both its anticancer efficacy and antiproliferative activity, 
as shown in figure 15D. Indeed, these two inhibitors showed a synergistic effect 
with nelfinavir, reducing tumor cell growth in nelfinavir dose-dependent 
manner. 
 
4.6 Nelfinavir induces the increase of ROS production and lipid 
peroxidation in breast cancer but not in normal cell lines 
 
   The degradation of akt protein and the presence of high percentage of 
necrotic cells in nelfinavir-treated cells suggested an involvment of a fast-
acting mechanism such as reactive oxygen species. To assess ROS production 
in these cells, I performed a FACS analysis through the observation of H2DCF-
DA oxidation. As shown in figure 16, nelfinavir induced time-dependent 
production of ROS with different trend in the analyzed cell-lines. The increase 
of ROS production was fast in MCF-7 cells, starting at 30minutes, and was 
progressively reduced until 24 hours of nelfinavir-treatment. MDA-MB231 
cells treated with this drug exhibited a slight increase of intracellular ROS 
levels within 3 hours, that gradually enhanced in a time-dependent manner. 
These different trends of ROS levels reflected also the cell-death schedule 
observed in these two cell lines. Therefore, the high levels of ROS at 30 
minutes in MCF7 cells could explain the earlier cell-death induction in MCF-7 
cells compared to MDA-MB231 cells. In both cell lines a massive ROS 
production rapidly caused necrosis, while a slight increase of ROS levels 
occurring in the second part of the time course was able to regulate apoptotic 
pathways as described in other studies (Chandra et al. 2000; Achanta and 
Huang 2004; Conklin 2004). On the contrary, in normal primary breast cell,  
only long term nelfinavir treatment induced a not statistically significant 
increase of ROS production. 
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Figure 16. Nelfinavir induces ROS accumulation in a time-dependent manner in breast 
cancer cells MDA-MB231, MCF-7 and primary breast epithelial cells  were subjected to 10µM 
nelfinavir treatment for 30 minutes-72 hours (h). ROS production was measured by H2DCF-
DA staining and fluorescence intensity was shown as representative FACS-based method (A) or 
expressed as MFI normalized to untreated cell values (B). Each value is the mean ±S.D. of 
three different experiments. *p< 0.05 compared to control cells. 
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Since ROS cause macromolecular damage with rapid attack to the 
polyunsatured fatty acids of the membrane, I investigated whether nelfinavir 
induced lipid peroxidation. To this aim, I treated MCF-7 and MDA-MB231 
cells with 10µM nelfinavir for 30 minutes, 3, 24 and 72 hours  and quantified 
the malondialdehyde (MDA) concentration, a lipid peroxidation marker, by 
colorimetric assay. As depicted in figure 17, while in MDA-MB231cells 
nelfinavir  induced a progressive increase of lipid peroxidation starting from 3 
hours up to 72 hours, in MCF-7 cells this effect began at 24 hours of treatment. 
No significative modification of lipid oxidation status was observed in normal 
cells, although 30 min nelfinavir incubation caused a slight reduction of lipid 
peroxidation in all analized cell lines. From this assay appeared an early 
detoxifying response of cells to redox state perturbation induced by the drug, 
that was suppressed after 3 hours in tumoral cells. These data indicated a 
protective response of normal cells to nelfinavir-induced oxidative stress, 
whereas breast cancer cell lines did not shown a full detoxifing capability. 
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Figure 17. Nelfinavir treatment causes an increased lipid peroxidation in tumor cells 
Breast cancer cells and normal mammary cells were treated with 10µM nelfinavir for the 
indicated time points, and processed as indicated in material and methods. Colorimetric 
analysis revealed the concentration of MDA (nM), a lipid peroxidation marker. The present 
data derived from three different experiments. *(p-value< 0.05) indicates statistical significance 
relative to control (ctrl). 
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4.7 Nelfinavir perturbs cell redox state by affecting ROS-scavengers 
enzymes 
 
To better investigate redox alterations induced by nelfinavir in breast 
cancer cells and identify the source of ROS production, I analyzed the activity 
of the main ROS detoxifying-enzymes: superoxide dismutase (SOD) and 
glutathione reductase (GR). In MDA-MB231 and MCF-7 cells, nelfinavir 
increased SOD activity in a time dependent manner (figure 18A). Since SOD 
acts both as antioxidant enzyme for removing superoxide anion and as ROS 
inducer for production of hydrogen peroxide, the increase of SOD activity 
could be a pro- and anti-oxidant condition. For this reason, the enhanced SOD 
activity after the treatment with nelfinavir could represent a source of ROS 
production as well as the effect of oxidative stress response. To better 
investigate the role of SOD, I analyzed SOD1 and SOD2 protein expression 
levels following nelfinavir treatment in breast cancer cell lines and normal 
breast epithelial cells. Western blot analysis revealed a time and cell-type 
dependent regulation of SOD 1 and SOD2 expression levels (figure 18B).  
 
 
 
Figure 18. Nelfinavir regulates SOD activity and expression in a time-dependent manner 
A) Breast cancer cells were treated with 10µM nelfinavir at indicated times and SOD activity 
(inhibition rate %) analyzed as indicated in Material and Methods. Values are representative of 
three independent experiments (means ± S.D., *p-value< 0.05). B) Protein lysates derived from  
MDA-MB231, MCF-7, or breast epithelial cells, treated with 10µM nelfinavir for the indicated 
time points, were immunoblotted with anti- SOD1 and anti-SOD2. β-actin was used as loading 
control. 
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 In particular, at an early time of 30 minutes of nelfinavir treatment, SOD1 
was upregulated in MDA-MB231 and in MCF7 cells, while SOD2 levels 
increased following 24 hours of treatment. Although also normal cells showed 
an increase of SOD1 and SOD2 expression at an early time of nelfinavir 
treatment, long term treatment did not affect the levels of SOD1 and SOD2. 
On the another hand, in tumoral cell lines, the initial  increase of SOD1 
and SOD2 levels was followed by a strong reduction of the expression of both 
protein expression at 72 hours of treatment. This analysis suggests an 
involvement of SOD1 at an early step of nelfinavir anti-cancer activity. 
 To determine whether SOD1 upregulation at this early stage was 
responsable for the increase of ROS production or rather it represented a ROS-
induced effect in breast cancer cells, I treated these cells with tocopherol, and 
analyzed SOD expression by western blot. As shown in figure 19, both the 
upregulation of SOD1 after 30 minutes of drug treatment and its reduction at 
24 hours, were dependent by ROS production, since the antioxidant tocopherol 
restored basal SOD1 expression levels. These data suggested that SOD1 and 
SOD2 do not act as ROS-producers but rather their activity and expression 
levels are regulated by reactive species following the treatment with nelfinavir. 
 
 
 
Figure 19. Nelfinavir-enhanced ROS levels modulate SOD1 expression 
MCF-7 cells, treated with 10µM nelfinavir ± 35µM tocopherol for 30 minutes or 24 hours, 
were lysed and subjected to western blot analysis for SOD1. β-actin was used as loading 
control. 
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To investigate whether other detoxifying enzymes were activated by 
nelfinavir-mediated oxidative stress, I measured the activity of GR at different 
times of nelfinavir treatment. As shown in figure 20, GR activity enhanced 
after 3 hours of drug incubation and was strongly reduced after 24 hours of 
treatment in MCF-7 or 48 hours in MDA-MB231. The rapid activation and the 
subsequent downregulation of GR activity reflected ROS production trend and 
SOD1 and SOD2 expression level changes. 
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Figure 20. Nelfinavir regulates GR activity 
Cells were treated with 10µM nelfinavir at indicated time points, then lysed and processed as 
indicated in Materials and Methods. GR activity is expressed in mU/ml, values are means± S.D. 
of three independent experiments.*p-value< 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
4.8 The disruption of akt-hsp90 complex in nelfinavir-treated cancer 
cells is ROS mediated 
 
In physiological conditions, ROS are very important regulators of many 
intracellular pathways such as cell proliferation and metabolism, but at higher 
concentration they can determine the opposite effects by blocking survival 
pathways and inducing apoptosis and necrosis. To investigate whether ROS 
were responsable for akt downregulation and akt/HSP90 complex dissociation, 
breast cancer cells were treated with nelfinavir in presence of antioxidant 
tocopherol, and HSP90/akt complex were co-immunoprecititated to perform 
western blot analysis. As shown in figure 21, in breast cancer cell lines, the 
presence of tocopherol impaired nelfinavir-induced disruption of akt/HSP90 
complex. This result puts ROS production as an earlier event than akt 
downregulation. According to literature, this result suggests an important 
correlation between high intracellular ROS levels and akt/HSP90 
downregulation (Beck et al. 2012; Sarkar et al. 2013). Because ROS promote 
disruption of akt/HSP90 complex in tumoral cells treated with nelfinavir, I also 
evaluated the protein expression levels of other two HSP90 clients such as 
cyclinD and ERα. Figure 21B shows that these proteins were reduced by 
nelfinavir treatment while the addition of tocopherol restored their expression 
levels at those of untreated cells.  
 
 
 
Figure 21. The nelfinavir-induced akt/HSP90 complex disruption is ROS-mediated 
A) MDA-MB231, MCF7 and breast epithelial cells were treated with 10µM nelfinavir and 
35µM tocopherol for 6 hours, and equal amounts of protein lysate were immunoprecipitated 
(IP) using akt antibody followed by immunoblotting with anti-HSP90 and anti-akt. B) MDA-
MB231 and MCF-7 cells were treated with 10µM nelfinavir and 35µM tocopherol for 24 hours 
and phospho-akt, akt, cyclin D, ERα, β-actin levels were monitored using the respective 
antibody by western blot on total lysate. β-actin immunoblotting was used as a loading control. 
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        4.9 The free radical scavenger tocopherol completely suppresses cell 
death induced by nelfinavir 
 
To confirm the primary role of ROS in the mechanism of action of 
nelfinavir, I assessed the capability of tocopherol to prevent nelfinavir-induced 
cell death. MCF-7 and MDA-MB231 cells were treated with nelfinavir for 24 
and 48 hours respectively, and necrosis and apoptosis were evaluated by 
annexin V/PI assay. The presence of tocopherol in tumor cells treated with 
nelfinavir impaired ROS overproduction and subsequent apoptotic and necrotic 
processes (figure 22). 
 
 
 
Figure 22. Nelfinavir induces tumor cell-death by increased ROS production 
MDA-MB231 and MCF-7 cells were treated with nelfinavir (for 72 and 24 hours respectively) 
in the absence or presence of 35µM tocopherol. Cell-death profile was examined by 
cytofluorimetric analysis of annexin V/ propidium iodide (PI) positivity. The cell percentage 
are reported in corresponding  areas of dot-plot. Three different experiments confirmed this cell 
distribution. 
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4.10 Identification of new series of nelfinavir-derivatives 
 
The study of the mechanisms at the basis of anti-cancer activity of 
nelfinavir and the identification of the main targets of the drug have accounted 
for and directed a chemical study of nelfinavir structure. The structure of 
nelfinavir can be fragmented into five moieties: the 2-methyl-3-hydroxy-
benzamide portion A, the S-phenyl group B, the tert-butyl carboxamide moiety 
C, the lipophilic dodecahydroisoquinoline ring D and the central hydroxyl 
group E (figure 23). The benzamide ring A in the predicted conformations 
superimposes well onto the aromatic groups of the co-crystallized inhibitors 
and plays a critical role in molecular recognition (Aronov et al. 2008). 
 
 
                          
Figure 23. Structure of Nelfinavir 
 
In this work we synthesized several peptidomimetics derived from 
nelfinavir. Peptidomimetics are caracterized by improved chemical accessibility 
and allow to obtain molecular diversity. The synthesized molecules mainteined 
crucial residues for the activity: A, B, C, D (figure 23) but the 
dodecahydroisoquinoline ring D was replaced with a 1,2,3,4-
tetrahydroisoquinoline ring to reduce the flexibility and remain the two 
aromatic rings A and B, introducing as A a phenilalanine (ND1) and a tyrosine 
(ND2) in order to mantain the hydroxilic group on the aromatic ring (figure 
24A). Viability assay revealed that ND1 e ND2 preserved anti-tumoral potential 
of nelfinavir at 10µM in MCF-7 cells (figure 24B). However, these two 
compounds  showed less efficacy in MDA-MB231 cells and more cytotoxic 
activity versus normal breast cell than nelfinavir. This result suggested that the 
new chemical modifications were not useful to improve anti-tumoral efficacy, 
although they highlighted the tridimensional pharmacophoric structure of 
nelfinavir.  
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Figure 24. ND1 e ND2 preserve nelfinavir cytotoxic activity in breast cancer cells 
A) Structure of ND1 and ND2. B) Cell viability analysis in MDA-MB231, MCF-7 and normal 
breast epithelial cells treated with different concentrations of ND1 or ND2 for 24 hours. Each 
value represents the mean ± S.D. of three different experiments.*p-value< 0.05. 
 
 
We also used this template to construct new heterocyclic systems designed 
as potential modulators of cell proliferation. We synthesized focused libraries 
of compounds based on the spiro (oxindole-3,3-thiazolidine) nucleus (series 
100) and the corresponding spiro[imidazo[1,5-c]-thiazole-3,3-indoline]-
2’,5,7(6H,7aH)-trione derivatives (series 200) (figure 25).  
 
 
 
 
Figure 25. Structure of series 100 and series 200 
In both series R = H, CH3, Br; R’ = benzyl derivatives or alkyl; R” = H or acyl derivatives. 
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I focused my attention on series 200 compounds, and tested their 
cytototoxic activity in MCF-7 as primary screening. The most part of these new 
compounds showed a lower IC50 than nelfinavir (table 3), suggesting that the 
novel chemical modification improved citotoxic efficacy of nelfinavir in breast 
cancer cells. Among these nelfinavir-derivatives, 4n proved to be the most 
potent compound with an IC50 of 50nM resulting as a new candidate for further 
biological studies.  
 
  
   Table 3 
Series 200 IC50 (M±SD)a
C R R1 R2 MCF-7
b
4a H H CH2C6H4(4-Cl) > 5
4b CH3 H CH2C6H4(4-Cl) 4.81±1.0
4c Br H CH2C6H4(4-Cl) 2.90±0.8
4d H H C6H4(4-Cl) 2.15 ±0.7
4e CH3 H C6H4(4-Cl) 2.12±0.7
4f Br H C6H4(4-Cl) 0.90±0.2
4g Br H C6H4(4-Cl) 3.0 ±0.20
4h H CH3 C6H4(4-Cl) 4.52±1.1
4i CH3 CH3 C6H4(4-Cl) 1.23±0.4
4j Br CH3 C6H4(4-Cl) 0.52±0.3
4k Br CH3 CH2C6H4(4-Cl) 0.27±0.1
4l Br CH3 C6H5 0.31±0.1
4m Br CH3 C6H4(4-CH3) 0.06±0.05
4n Br CH3 Cyclohexyl 0.04±0.01
4o CH3 CH3 Cyclohexyl 1.20±0.6
4p H CH3 Cyclohexyl 2.30±0.8
4q Br H Cyclohexyl 0.22±0.1
4r Br CH3 Cyclohexyl 2.01±0.9
5a H COC6H4(4-Cl) H 1.01±0.6
5b CH3 COC6H4(4-Cl) H 3.46±0.9
5c Br COC6H4(4-Cl) H 0.15±0.1
5d Br Cyclohexyl H 2.08±0.8
6b CH3 COC6H4(4-Cl) 2.78±0.9
6c Br COC6H4(4-Cl) 0.86±0.4
6d Br Cyclohexyl 1.63±0.6
 
 
Table 3. 4n reduces MCF-7 cells viability in a nanomolar range 
Screening of nelfinavir-derivative compounds by cell viability analysis in MCF-7 cells. The 
numbers reported represent IC50 values (µM) ± S.D. Each value is the mean of three 
indipendent experiments. 
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4.11 4n is the most potent nelfinavir-derivative with anti-cancer 
activity 
 
I further investigated the cytotoxic effect of 4n in MDA-MB231 cells and 
primary normal breast cells. Figure 26 demonstrated that 4n was also capable to 
reduce MDA-MB231 cell viability without affecting normal cells viability 
when it was used at 50nM-1µM concentration range. Subsequently, I evaluated 
whether 4n compound retained the same biological effects and molecular 
targets of the lead compound, nelfinavir. To this purpose, I analyzed akt 
regulation and ROS production in MCF7 cells treated with 4n. As shown in 
figure 26, 4n as well as nelfinavir reduced akt expression levels after 24, 48 and 
72 hours of treatment. The FACS analysis of ROS intracellular levels revealed 
that, likewise nelfinavir, also 4n is able to induce ROS production.  
 
 
 
 
Figure 26. 4n preserves anti-cancer molecular mechanism of nelfinavir  
A) Chemical structure of 4n. B) MTT assay performed in MDA-MB231, MCF-7 and primary 
breast epithelial cells, treated with indicated concentration of 4n for 24 hours. C) Western blot 
analysis of phospho- and total akt in MCF-7 cells treated with 50nM 4n at indicated time 
points. β-actin immunoblotting was used as a loading control. D) MCF-7 cells were treated with 
50 nM 4n and after 30 minutes, ROS production was assessed in terms of oxidation of H2DCF-
DA and compared to control (ctrl) cells. Each value represents the mean ± S.D. of three 
different experiments.* p-value< 0.05. 
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5. DISCUSSION 
 
Identification and characterization of new pharmacological activities from 
existing drugs represents an effective way to accelerate the translation of 
discoveries from the bench to clinical applications.  HIV-PI, rationally designed 
to block viral protease, have shown an anti-tumoral activity in several cancers, 
thus encouraging the study of the intracellular pathways at the basis of their 
anti-cancer activity. Among HIV-PIs, nelfinavir is considered the most potent 
antitumoral compound, and has entered several clinical trials as either a 
chemotherapeutic agent or a radiosensitizer for cancer therapy (Chow et al. 
2006; Yang et al. 2006b; Gills et al. 2007). Many studies suggested that 
inhibition of PI3k and akt signalling are responsible for its pro-apoptotic effects 
on tumor cells, enhancing the efficacy of radiation therapy in different types of 
cancer (Yang et al. 2006b; Gills et al. 2007; Gupta et al. 2007; Bernstein and 
Dennis 2008; Plastaras et al. 2008). Despite extensive studies on the anticancer 
and radiosensitizing activity of nelfinavir, the specific molecular mechanism 
underlying its antiproliferative activity and its inhibitory effect on PI3K and akt 
signaling pathway remains unknown. Aim of the present thesis is to study the 
anticancer activity of nelfinavir in breast cancer model, where few and 
controversal data prevent its employment in clinical trials. Breast cancer is the 
most frequent cancer in the female population and, despite recent advances in 
chemo- and endocrine therapy, significant proportion of breast cancer patients  
fail to heal for the lack of selectivity in the activity of chemotherapeutics and, 
and for the acquisition of chemoresistance and endocrine resistance. Moreover, 
it has been demonstrated that PI3K mutations in addition to alterations of other 
pro-tumoral molecules play a role in resistance to some of the endocrine 
therapies. In this context, I investigated whether nelfinavir exerts anti-cancer 
activity in breast cancer cells, and I evaluated the role of PI3K/akt pathway in 
drug-mediated anti-proliferative effect. To this aim, I used breast cancer cell 
lines that were either estrogen-dependent (MCF-7) or estrogen and 
progesterone receptor negative (MDA-MB231). MCF-7 and MDA-MB-231 
cell lines are dependent on Akt for proliferation (Fujita et al. 2002; Acosta et al. 
2003), making them also informative for the effects of nelfinavir on Akt 
signaling, that may regulate breast cancer proliferation and survival. Firstly, I 
validated the anti-proliferative and cytotoxic activity of nelfinavir in a panel of 
different tumor types, focusing the attention on breast cancer cell lines. I 
observed that 10μM nelfinavir was able to reduce tumor cell viability without 
affecting normal primary breast cell-viability/growth. Extensive 
pharmacokinetics studies have shown that nelfinavir has an average peak 
plasma level of 8-10µM, that represents the IC50 used for breast cancer cell 
lines, and suggesting that it may be effective in breast cancer patients with the 
current dosage regimen (Bernstein and Dennis 2008). In this work, I 
demonstrated that nelfinavir induces cell-cycle arrest in G0/G1 phase and 
subsequently cell death in MDA-MB231, whereas it causes directly the death in 
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MCF-7 cells. FACS analysis of cell-cycle was further supported by the 
observation of changes in the expression of cell-cycle regulators. Indeed, 
nelfinavir reduced the levels of phosphorylated Rb, cyclin A, cyclin B, cyclin 
D, increased the expression levels of p21 in breast cancer cell lines but not in 
normal cells. Furthermore, cyclin E resulted downregulated only in MDA-
MB231. Although tumor cell lines showed a similar protein expression profile, 
biological effects of nelfinavir treatment resulted different in MDA-MB231 and 
MCF-7 cells. Indeed, whereas in the former I observed a Go/G1 block, MCF-7 
cell-cycle was not affected by nelfinavir. Probably, the different basal levels of 
expression of cyclins and the significant reduction of cyclin E limited to MDA-
MB231 cells, could play a role in the different response of cell lines to 
nelfinavir in cell-cycle progression. It is also possible that other mediators that I 
did not investigated mediators are involved in this different cellular response.  
The study of apoptotic and necrotic populations, differentiated  by annexin 
V/PI staining, and the evaluation of apoptotic markers such as Bak, cytocrome 
C and caspase 9, revealed a fast induction of necrosis followed by an apoptotic 
process both in MDA-MB231 and in MCF-7 cells. These results suggest a 
direct cytotoxic action of nelfinavir on tumor cell. A comparison between the 
death profile of these cell lines pointed out different cell death timetables. 
Indeed, 12 hours of nelfinavir treatment increased to 20% the necrotic cells 
percentage, achieving about 50% of necrotic and apoptotic cells following 48 
hours of treatment in MCF-7 cells while more than 72 hours of drug treatment  
were required to determine a massive increase of cell-death in MDA-MB231 
cells. Therefore, nelfinavir-treated cells increased the expression levels of pro-
apoptotic mitochondrial factor Bak, induced a citochrome c release from 
mitochondria, and subsequently the activation of caspase 9 in a time-dependent 
manner. So, the short-term nelfinavir-treatment induced cell-death directly in 
MCF-7cells, and did not have a prominent cytotoxic effect in MDA-MB231, 
which resulted blocked in G0/G1 phase. However, prolonged cell-cycle block 
induced necrosis and activation of the apoptotic process. These data suggest a 
greater resistance of MDA-MB231 cells to nelfinavir-induced cytotoxicity 
compared to MCF-7 cells. 
It was well established that inhibition of akt phosphorylation is an 
important mechanism by which nelfinavir exerts anti-tumour activity in several 
cancer types (Gupta et al. 2005; Yang et al. 2006b; Cuneo et al. 2007), although 
its involvment in breast cancer has not been elucidated. My results 
demonstrated that nelfinavir is effectively able to downregulate akt signaling in 
breast cancer cell models, as suggested by reduction of phosphorylated-akt and 
akt-targets such as cyclin D, PRAS40, MDM2, and Bcl-2 in tumor cells but not 
in normal cells. Surprisingly, also total akt was reduced by the drug, leading us 
to analyze akt mRNA expression levels and akt protein stability. Our data 
suggested that nelfinavir-mediated akt regulation does not accurr at 
transcriptional level, but rather nelfinavir enhances akt protein turnover by 
affecting akt stability. Because akt stability is mainly dependent from its 
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association with chaperone HSP90, I evaluated the association between akt and 
HSP90 by co-immunoprecipitation assay. The result demonstrated that 
nelfinavir reduces akt/HSP90 association after 6 hours of treatment without 
affecting akt and HSP90 expression levels. The nelfinavir-mediated disruption 
of HSP90/akt complex could explain the significant and fast de-
phosphorylation of akt and subsequent downregulation of total akt. Indeed, akt 
when dissociated from its chaperon became more sensitive to PP2A-mediated 
dephosphorylation and to ubiquitination and degradation by proteasome (Sato 
et al. 2000). To determine whether nelfinavir induced akt degradation and 
whether proteasome mediated this process, breast cancer cells were treated with 
MG132, a proteasome inhibitor, and akt was detected by western blot analysis. 
Proteasome inhibitor impaired  nelfinavir effects restoring akt protein levels, 
thus suggesting that nelfinavir induced akt degradation via proteasome. 
Although in different breast cancer cell lines, the effect of nelfinavir on 
akt/HSP90 complex dissociation has been recently observed (Shim et al. 2012). 
To confirm the involvement of akt pathway and HSP90 activity in nelfinavir-
mediated anti-cancer effects, I determined whether canonical inhibitors of akt 
pathway or HSP90 activity were able to reduce breast cancer cell-growth. Both 
17-AAG and LY294002 reduced cell-growth and determined a downregulation 
of akt, thus confirming the important role of HSP90 in akt stability and in 
breast cancer cell viability. However, nelfinavir showed more efficacy than the 
other two inhibitors, suggesting, in agreement with existing literature (Gills et 
al. 2007; Gupta et al. 2007), that nelfinavir has a broad spectrum of activity not 
only restricted to akt downregulation. Moreover, the combination of nelfinavir 
with 17-AAG and LY294002 improved both its anticancer efficacy and 
antiproliferative activity. Indeed, these two inhibitors showed a synergistic 
effect with nelfinavir, reducing tumor cell growth in a nelfinavir-dose-
dependent manner. 
Contrary to the hypothesis of HSP90 as primary nelfinavir target (Shim et 
al. 2012), I demonstrated that akt/HSP90 disruption is dependent upon 
nelfinavir-induced oxidative stress. A number of evidences  led me to 
hypothesyze that ROS could play a primary role in anti-cancer activity of 
nelfinavir: the presence of high necrotic cell percentage following nelfinavir 
short-term treatment in breast cancer cells; the observation that dissociation of 
HSP90/client complex could be due to oxidation and loss of function of the 
chaperon protein (Beck et al. 2012; Sarkar et al. 2013); clinical studies on 
nelfinavir as anti-viral drug that revealed an involvement of ROS in the side-
effects development (Moskowitz and Kukin 1999; Irani 2000; Bloch-Damti and 
Bashan 2005; Rudich et al. 2005; Gotoh and Mori 2006). For these reasons, I 
evaluated ROS production in breast cancer cells and in normal breast cells. The 
analysis revealed a significant increase of ROS intracellular levels limited to 
tumor cells. The increase of  ROS production was fast in MCF-7 cells and was 
progressively reduced until 24 hours of nelfinavir-treatment. MDA-MB231 
cells treated with this drug exhibited a slight increase of intracellular ROS 
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levels within 3 hours, that gradually enhanced in a time-dependent manner. The 
different trends of ROS levels reflected also the cell-death schedules observed 
in these two cell lines. Therefore, the high levels of ROS at 30 minutes in 
MCF7 cells could explain the earlier cell-death induction compared to MDA-
MB231 cells. In both cell lines, a massive ROS production caused necrosis, 
while a slight increase of ROS levels occurring in the second part of the time 
course was able to regulate apoptotic pathways, as described in previous 
studies (Chandra et al. 2000; Achanta and Huang 2004; Conklin 2004). The 
observation of ROS-generating capability of nelfinavir is further supported by 
the observation of drug-mediated increase of lipid peroxidation. Comparing 
tumor and normal breast cells it resulted evident that, although both cell types 
showed an early protective response to oxidative stress, only normal cells 
restored basal redox status, whereas cancer cells did not retain full detoxifying 
capability. It has been well established that breast cancer cells present higher 
ROS levels than normal cells in basal conditions (Toyokuni et al. 1995; 
Portakal et al. 2000; Brown and Bicknell 2001), in order to promote genome 
instability and alterations in cell signaling processes related to survival, 
proliferation, resistance to apoptosis, angiogenesis and metastasis (McEligot et 
al. 2005; Sablina et al. 2005; Reliene and Schiestl 2006; Lu et al. 2007).  Since 
tumor and normal cells show different redox balance, one interesting 
therapeutic strategy might be the induction of cytotoxic oxidative stress (De 
Miguel and Cordero 2012). I demonstrated that anti-cancer effects of nelfinavir 
are due to the capability of redox status regulation, thus explaining its greater 
efficacy in tumor cells compared to normal cells. The different behaviour 
between cancer and normal cells could be related to loss of activity or 
impairment of antioxidants (Oberley and Buettner 1979; Oberley et al. 2004; 
Ridnour et al. 2004; Sinha et al. 2009), or to an upregulation of ROS-producer 
enzymes (Sundaresan et al. 1996; Brown et al. 2000; Meitzler et al. 2013). To 
further investigate the molecular source of nelfinavir-induced ROS, I 
determined whether nelfinavir enhances ROS levels by downregulation of 
antioxidant signaling. Among the different intracellular detoxifying-enzymes 
that are differently modulated in breast cancer cells compared to normal cells, 
SOD represents the main  redox status regulator (Oberley and Buettner 1979; 
Sinha et al. 2009; Radenkovic et al. 2013). Surprisingly, my results 
demonstrated that nelfinavir increased SOD activity in a time-dependent 
manner in breast cancer cell lines. However, the increase of SOD activity has 
been reported not only as antioxidant but also as pro-oxidant condition. Indeed, 
since SOD acts both as antioxidant enzyme for removing superoxide anion and 
as ROS inducer for production of  hydrogen peroxide, the enhanced SOD 
activity after the treatment with nelfinavir could represent a source of ROS 
production as well as the effect of oxidative stress. My results suggested that 
nelfinavir regulates not only the activity but also the expression levels of SOD1 
and SOD2 both in tumor and normal breast cells. In particular, it determines a 
rapid increase of SOD1 (at 30 min) and SOD2 (at 24 hours) levels, followed by 
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restoring of basal levels in normal cells or strong reduction of their expression 
in cancer cells. To determine whether SOD1 upregulation at an early state was 
responsable for the increase of ROS production, or rather it represented a ROS-
induced effect in breast cancer cells, I analyzed SOD expression in cells treated 
with nelfinavir in the presence of tocopherol. The analysis  revealed that both 
the upregulation of SOD1 after 30minutes of drug treatment and its subsequent 
reduction, were dependent by ROS production, since antioxidant restored basal 
SOD1 expression levels. These data suggest that SOD1 is not the primary 
target of nelfinavir, but is first upregulated, and then downregulated following 
redox status modification induced by the drug. Another investigated 
antioxidant, GR, is regulated by nelfinavir, that primarily enhances and 
subsequently reduces GR activity. The rapid activation and the following 
downregulation of GR activity reflected ROS production kinetics and the 
expression of SOD1 and SOD2. While it was well established that detoxifying 
enzymes can be activated and upregulated by ROS (De Miguel and Cordero 
2012), their decrease in oxidative stress condition is not completely understood. 
However many authors suggest that decrease of SOD (Manoharan et al. 2004; 
Ezzi et al. 2007) and GR activity could be related to the generation of free 
radicals that cause direct damage to the enzyme (Veal et al. 2007). It is possible 
that also nelfinavir-induced oxidative stress determines a reduction of 
antioxidants levels by oxidation, which further enhances ROS levels. Another 
explaination might be that the nelfinavir-mediated downregulation of akt 
signaling causes a reduction of antioxidant enzymes expression by NFkB 
regulation (Rojo et al. 2004). In physiological conditions, ROS are involved in 
the regulation of cell proliferation and metabolism, but at higher concentrations 
they can determine the opposite effects by blocking survival pathways and 
inducing apoptosis and necrosis. To investigate whether ROS are responsible of 
AKT downregulation and akt/HSP90 complex dissociation, breast normal and 
cancer cells were treated with nelfinavir in presence of antioxidant tocopherol. 
My results demonstrated that in breast cancer cell lines, the presence of 
tocopherol impaired nelfinavir-induced disruption of akt/HSP90 complex, 
whereas nelfinavir did not affect akt/HSP90 association in normal cells. These 
results put ROS production as an earlier event than akt downregulation. 
According to the literature, these results demonstrate an important correlation 
between high intracellular ROS levels and akt/HSP90 downregulation (Clark et 
al. 2009; Beck et al. 2012; Sarkar et al. 2013). To confirm the primary role of 
ROS in the mechanism of action of nelfinavir, I assessed the capability of 
tocopherol to prevent nelfinavir-induced cancer cell death. My analysis showed 
that the presence of antioxidant in cells treated with nelfinavir, impaired 
apoptosis and necrosis development. Although nelfinavir induced cell death in 
the two breast cancer cell lines I tested, the data also indicate that the cell lines 
respond quite differently to nelfinavir, regarding the effect on cell cycle and 
timetable of ROS production and cell-death. This variation might be due to the 
different hormone receptor status of the cells, but also to different redox 
70 
 
adaptation and to the different malignancies of the tumours from which these 
cell lines have been derived.  
It is plausible that oxidative stress produced by nelfinavir affects other 
pathways in addition to akt/HSP90 signaling to cause cell death. Indeed, other 
HSP90 clients resulted downregulated by the drug such as ER and cyclin D, 
leading to the hypothesis that many oncogenic kinases HSP90 clients, such as 
Raf-1, Bcr-Abl and ErbB2 (Zuehlke and Johnson 2010), might be regulated by 
the drug. This fact could explain the broad spectrum of nelfinavir anti-cancer 
molecular mechanisms and the large amount of molecular targets reported in 
the literature.  
Therefore, the suggested temporary sequence of nelfinavir activities in 
breast cancer cells is as follows: pertubation of redox state with increase of 
ROS production; akt/HSP90 disruption by oxidation; akt degradation via 
proteasome; cell cycle block and/or cell death. These nelfinavir-mediated 
biological effects are represented in figure 27. 
 
 
 
 
Figure 27. A possible nelfinavir mechanism of action in breast cancer 
 
Despite this wide spectrum of activity, nelfinavir is not very potent, since 
it requires 10µM concentration to achieve cell activity, and the maximum 
concentrations achieved in patients are 7-9µM (Bernstein and Dennis 2008). 
Therefore, long term treatment with this concentration of nelfinavir can cause 
important side effects. These evidences drove me to characterize nelfinavir 
structure in order to synthesize new peptidomimetics with anti-cancer activity. 
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In this work we synthesized nelfinavir-derivatives, manteining crucial lead 
compound-residues for the activity. The first two compounds ND1 and ND2 
preserved anti-tumoral efficacy of nelfinavir, even if they showed more 
cytotoxic activity than nelfinavir versus normal breast cells. These results 
suggested that the new chemical modifications were not useful to improve anti-
tumoral efficacy although they highlighted the tridimensional pharmacophoric 
structure of nelfinavir, that was important for the development of second class 
of nelfinavir-derivatives, named series 200. The most part of these new 
compounds showed a lower IC50 than nelfinavir, suggesting that the novel 
chemical modification improved citotoxic activity of nelfinavir in breast cancer 
cells. Among these nelfinavir-derivatives, 4n resulted the most potent 
compound, with an IC50 of 50 nM in breast cancer cells and low toxicity versus 
normal cells.  Therefore, the analysis of akt expression and ROS production in 
breast cancer cells revealed that 4n as well as nelfinavir reduced akt expression 
levels and induced a significant increase of ROS intracellular levels. 
In order to better define the anti-cancer activity of 4n, I investigated new 
hypothetical molecular targets of this new compound. Starting from the 
chemists observation that 4n, as well as all class of compounds, show structural 
analogy with nutlin, I determined whether 4n affects p53-MDM2 interaction in 
MCF7 cells. This part of study has been the subject of publication attached to 
the present thesis (Bertamino et al. 2013), that demonstrates a direct 
involvement of 4n in a p53/MDM2 dissociation with subsequent p53 
accumulation and induction of p53-dependent apoptosis. 
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6. CONCLUSIONS 
 
Chemotherapy resistance remains a major obstacle for successful breast 
cancer treatment. Thus, the continuous development of new anti-cancer drugs 
could help address drug resistance by offering a broader spectrum of alternative 
anticancer agents. Nelfinavir, initially designed to block HIV-protease, has 
shown an important anti-cancer activity by affecting many intracellular 
pathways involved in tumor cell proliferation and cell-death resistance 
mechanisms. Elucidation of its mechanism of action could have important 
implications in the development of nelfinavir and its analogs as new anticancer 
agents. In the present study, I demonstrated that nelfinavir reduces breast 
cancer cell viability/growth by induction of cell-cycle block or cell-death, 
depending on cell line. Indeed, nelfinavir directly causes necrosis and apoptosis 
in MCF-7 while it determines cell-cycle arrest in G1 phase and subsequent cell-
death in MDA-MB231cells. 
 Investigating the role of akt pathway in nelfinavir mediated cycle arrest 
and/or apoptosis, I can assert that nelfinavir strongly reduces akt signaling,  
proving this drug as effective chemotherapeutic agent or a radiosensitizer for 
cancer therapy. I have also shown that akt downregulation is related to a 
dissociation of akt/HSP90 complex that causes akt via proteasome degradation. 
The use of specific HSP90 or akt signal inhibitors confirmed the important 
function of akt/HSP90 complex in breast cancer cell proliferation. In addition, 
nelfinavir resulted more effective than these two inhibitors to reduce cell 
growth, suggesting that it has a  broad spectrum of activity, not only restricted 
to akt downregulation.  
 Importantly, I proved that both akt/HSP90 disruption and cell-death 
induced by nelfinavir in breast cancer cells, are related to ROS production. 
Indeed, the analysis of antioxidant enzymes such as SOD and GR revealed that 
nelfinavir induces redox status alterations, thus leading to oxidative stress. 
 These findings sustained both design and identification of novel 
nelfinavir-derivatives. I presented a new class of peptidomimetics derived from 
nelfinavir with enhanced anti-cancer efficacy. Among these compounds, 4n 
represents the most potent compound, which retains nelfinavir molecular 
target, working in a nanomolar range of concentration compared to 10µM 
nelfinavir. However, further studies are needed to better define all 4n-
molecular and cell targets, as well as its anti-cancer efficacy in vivo. 
Development of novel compounds capable to selectively inhibit tumor 
cell growth with more efficacy than actual chemotherapeutic agents is urgently 
required for cancer therapy, thus my work provides a molecular basis to explain 
the broad-spectrum anti-cancer effect of nelfinavir and prepare the ground for 
the development of new nelfinavir derivatives with more specific anti-cancer 
activity. 
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